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ABSTRACT

Subspecies B1 human adenoviruses (HAdVs) are important causes of acute
respiratory disease in pediatric and military recruit populations. Although extensive
epidemiological data document the genetic diversity of these human pathogens, little is
known about the relevance of this genetic diversity on the pathogenesis and fitness of
subspecies B1 HAdVs. Additionally, the unique molecular biology of these pathogens is
understudied compared to the species C HAdV serotypes 2 and 5. One of the uniquely
diverse regions of the HAdV genomes is the early region 3 (E3) transcription unit. These
genes are implicated in pathogenesis, host-species specificity, and the modulation of the
host immune response to infection. Subspecies B1 HAdVs encode a set of novel open
reading frames (ORFs) within the E3 region, including E3-20.1K, E3-20.5K, and E310.9K. ORF E3-10.9K is highly polymorphic among subspecies B1 HAdVs, and it
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displays extensive variation among strains of serotypes 3 and 7.

In an effort to

understand the role ORF E3-10.9K plays in the context of subspecies B1 HAdV
infectious cycle and fitness in nature and the biological implications of the observed
polymorphism, a biochemical characterization of ORF E3-10.9K-encoded proteins, the
investigation of membrane permeabilizing acitivity of these proteins, and the examination
of growth phenotypes of virus mutants lacking ORF E3-10.9K was undertaken. This
research showed that ORF E3-10.9K was expressed late in infection from the HAdV
major late promoter and that its products were N- and O-glycosylated, similar to E311.6K/adenovirus death protein (ADP) of species C HAdV. However, ORF E3-10.9Kencoded protein orthologs showed a subcellular localization distinct from the nuclear
envelope localization of the E3-11.6K/ADP. Proteins with a hydrophobic domain were
capable of permeabilizing membranes in an E. coli expression system, but not in a
mammalian expression system. Subspecies B1 HAdV mutants lacking ORF E3-10.9K
displayed similar virus growth and egress kinetics as control subspecies B1 HAdVs
containing ORF E3-10.9K.

These data suggested that ORF E3-10.9K is not the

subspecies B1 HAdV equivalent of species C HAdV E3-11.6K/ADP.
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Chapter 1: Introduction

Human adenoviruses (HAdV) are recognized etiological agents of acute
respiratory, gastrointestinal, and conjunctival infections in pediatric, military recruit, and
immunocompromised populations. The HAdV serotypes classified within subspecies B1
(HAdV-3, HAdV-7, HAdV-16, HAdV-21, and HAdV-50) are particularly important
causes of acute respiratory infections, which can result in severe clinical manifestations
or fatal outcome (Carballal et al., 2002; Kim et al., 2003; Lang et al., 1969; Videla et al.,
1999).

Subspecies B1 HAdV infection is linked to the development of long-term

respiratory sequelae in patients (Becroft, 1971; Herbert et al., 1977; Similä et al., 1981).
Although a vaccine to protect against HAdV-7 and the species E HAdV serotype 4
infections is licensed for use in military recruits, there is currently no vaccine available to
the civilian population.
Despite the importance of subspecies B1 HAdVs in the etiology of severe, acute
respiratory infections, little is known about their unique molecular biology.

Most

characterizations of adenoviruses (AdV) and their gene products have focused almost
exclusively on HAdV-2 and HAdV-5, both members of species C HAdV. However, a
wide range of associated clinical disease and viral genomic content exists among HAdV.
The limited study of non-species C HAdV molecular biology has hindered our ability to
address questions regarding the molecular basis of HAdV pathogenesis, specifically with
regards to subspecies B1 HAdV infections.
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Extensive intraserotypic genetic diversity within subspecies B1 HAdVs is well
documented (Golovina et al., 1991; Kajon and Wadell, 1994; Li and Wadell, 1986; Li
and Wadell, 1988). The existence of genomic variants (also known as genome types) of
subspecies B1 HAdV serotypes is well-established and detected primarily by restriction
enzyme analysis of the viral genomes. The circulation of these genomic variants in
human populations is often geographically restricted. Over time, these genomic variants
can spread to new geographic areas and take over as the predominant circulating genomic
variant (Erdman et al., 2002; Golovina et al., 1991; Wadell et al., 1980). These shifts are
correlated with an apparent increased severity of associated disease (Erdman et al., 2002;
Kajon and Wadell, 1994; Kajon et al., 1996; Larranaga et al., 2000; Wadell et al., 1980;
Wadell et al., 1985). However, the selective pressures driving these shifts and the
emergence of new genomic variants are poorly understood. The molecular basis of the
apparent increase in severity associated with these shifts is also unclear. Our limited
knowledge of subspecies B1 HAdV molecular biology has hindered our ability to
understand the impact genetic diversity plays in the evolution of these diverse viruses.
The early region 3 (E3) transcription unit has attracted intense interest within the
adenovirology field.

This transcription unit encodes non-structural protein products

primarily involved in modulating the host response to infection. The E3 transcription
unit is present only in the genomes of members of the genus Mastadenovirus and in the
genomes of some members of the genus Siadenovirus (Davison et al., 2003), and is
highly diverse in its coding capability. For HAdV, the E3 transcription unit is a hot spot
of genetic diversity, with species-specific arrays of open reading frames (ORFs) (Burgert
and Blusch, 2000). Previous work on the E3 transcription unit supports its role in
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pathogenesis, host species specificity, tropism, and immune evasion (Belak et al., 1986;
Ginsberg et al., 1989; Linne, 1992; Sparer et al., 1996). Because of the important role the
E3 transcription unit plays in virus-host interactions, natural variation among HAdV in
the E3 transcription unit could account for differences in the manifestation of clinical
disease caused by HAdV. However, experimental work on the E3 ORFs has focused
almost exclusively on species C HAdVs.

This leaves a significant gap in our

understanding of the role species-specific E3 ORFs play in the pathogenesis of nonspecies C HAdV infections, including subspecies B1 HAdV infections.
Three subspecies B1 HAdV-specific E3 ORFs are currently recognized: E320.1K, E3-20.5K, and E3-10.9K. The functions of the products of these ORFs for the
subspecies B1 HAdV life cycle are unknown.

ORF E3-20.5K-encoded protein is

expressed throughout infection and is N- and O-glycosylated (Hawkins and Wold, 1995a;
Hawkins and Wold, 1995b).

ORF E3-20.1K and ORF E3-10.9K have not been

extensively characterized. However, transcripts containing ORF E3-10.9K and ORF E320.1K are detected in infected cells (Kajon et al., 2005; Signäs et al., 1986). These three
E3 ORFs unique to subspecies B1 HAdV are attractive candidates for study to understand
the molecular basis of subspecies B1 HAdV pathogenesis.
For this dissertation, I focused on the functional and structural characterization of
ORF E3-10.9K and its encoded polypeptide products. Although transcripts containing
ORF E3-10.9K are detected in cells infected with subspecies B1 HAdVs (Kajon et al.,
2005), a more extensive analysis of the expression of this coding region and the protein
products has not been carried out. Previous work has shown that ORF E3-10.9K is
highly polymorphic among subspecies B1 HAdVs (Kajon et al., 2005). As will be
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discussed in Chapter 2, this ORF encodes polypeptide products that range in predicted
size from 4.8 kDa to 10.9 kDa. Some genomic variants of HAdV-7 and HAdV-3 are
predicted not to encode a polypeptide from this ORF due to a mutated ATG start codon
(Kajon et al., 2005). The ORF E3-10.9K polymorphism is striking in the variety of
mutations that exist within an individual subspecies B1 HAdV serotype, particularly in
HAdV-7 and HAdV-3. This naturally occurring intraserotypic diversity has not been
described for any other coding region of the HAdV genome, and offers the unique
opportunity to investigate genetic diversity of HAdV in the context of virus fitness and
pathogenesis.
We hypothesized that the ORF E3-10.9K-encoded products function in the
efficient release of progeny virions from the host cell by permeabilization of host cell
membranes. Several observations led us to this hypothesis. First, ORF E3-10.9K is in an
analogous location in the E3 transcription unit to the previously characterized species C
HAdV E3-11.6K/adenovirus death protein (ADP) (Tollefson et al., 1992).

E3-

11.6K/ADP is a late, glycosylated and palmitoylated non-structural viral protein involved
in the efficient release of virus progeny from the host cell at the end of infection,
although the mechanism by which E3-11.6K/ADP carries out this function is currently
unknown (Hausmann et al., 1998; Scaria et al., 1992; Tollefson et al., 1996a; Tollefson et
al., 1996b). ORF E3-10.9K predicted products and E3-11.6K/ADP are similar in size and
contain a hydrophobic domain. However, ORF E3-10.9K-encoded protein products and
E3-11.6K/ADP share little sequence similarity. Second, ORF E3-10.9K-encoded protein
products share similarities with a class of viral proteins known as viroporins. The term
viroporin is used to describe a group of virus-encoded proteins that share similar
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structural characteristics and function (Carrasco, 1995; Gonzalez and Carrasco, 2003).
These characteristics are small size (60-120 amino acids), one or more hydrophobic
domains, polybasic regions, and aromatic residues in or near the hydrophobic domain(s)
(Gonzalez and Carrasco, 2003). Additionally, viroporins play a role in the efficient
release of virus progeny at the end of infection, and are thought to carry out this function
through a mechanism that involves the permeabilization or disruption of host cell
membranes (Gonzalez and Carrasco, 2003). ORF E3-10.9K predicted protein products
meet the structural criteria to be considered candidate viroporins.
Because of the observed similarities between ORF E3-10.9K predicted protein
products, species C HAdV E3-11.6K/ADP, and viroporins, we hypothesized that ORF
E3-10.9K-encoded products function in the efficient release of progeny virions from the
host cell by permeabilization of host cell membranes. In accordance with this hypothesis,
we predicted that ORF E3-10.9K and its protein products would be expressed at late
times post infection (pi). Additionally, we predicted that the proteins would localize to
host cell membranes and permeabilize membranes to small molecules. Finally, if ORF
E3-10.9K-encoded protein products functioned as we hypothesized, mutant subspecies
B1 HAdVs that lacked the ability to express these proteins would be predicted to exit the
host cell less efficiently than viruses that did express the proteins.
The main goal of this work was to carry out a characterization of ORF E3-10.9Kencoded protein products to understand their role in the subspecies B1 HAdV life cycle.
Additionally, by examining this polymorphic ORF we strove to gain an understanding of
the role ORF E3-10.9K-encoded protein products would play in subspecies B1 HAdV
fitness and evolution. This work was a first step toward determining the implications of
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naturally occurring genetic diversity among subspecies B1 HAdV for viral fitness,
evolution, and pathogenesis.
The specific aims of the research described in this dissertation were to:
(1)

Carry out a biochemical characterization of ORF E3-10.9K and its predicted
protein products

(2)

Investigate the membrane permeabilizing activity of ORF E3-10.9K-encoded
proteins

(3)

Examine the role of ORF E3-10.9K in B1 HAdV growth and progeny virion
egress

6

Chapter 2: Background

Adenoviruses
Structure. Viruses of the Family Adenoviridae have non-enveloped, icosahedral
capsids surrounding an approximately 36 kbp-long double-stranded DNA genome. The
genome is covalently attached at the 5’ and 3’ ends to the terminal protein, which is
involved in viral genome replication. The icosahedral virus particles are approximately
90 nm in diameter and are composed of several structural proteins.

Hexons (240

capsomers) and pentons (12 capsomers) constitute the majority of the surface structure of
the AdV capsid. Hexon capsomers are composed of a trimer of the hexon polypeptide,
and penton capsomers are composed of the penton base and an associated, projecting
fiber protein (Ginsberg et al., 1966) (Fig. 1). The fiber proteins are involved in primary

Figure 1. Adenovirus virion. Important structural components of the adenovirus virion
are indicated, including capsid proteins (hexon, fiber, and penton base) and the viral
dsDNA genome associated with the terminal protein and surrounded by pVII. Adapted
from ICTVdb, 2002.
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receptor binding (Lonberg-Holm et al., 1969). Minor capsid proteins include proteins
VIII, IX, VI, and IIIa. These proteins are involved in stabilizing the capsid structure,
endosomal membrane disruption during viral entry into the host cell, and assembly.
Virion core proteins are located on the interior of the viral capsid and include proteins V,
VII, μ, and the terminal protein. Proteins V, VII, and μ are thought to condense the viral
DNA within the core of the capsid (Russell, 2009).
Classification and taxonomy. The Family Adenoviridae currently includes four
genera:

Atadenovirus, Aviadenovirus, Mastadenovirus, and Siadenovirus.

A fifth

unassigned genus containing sturgeon AdV is currently under review by the International
Committee on the Taxonomy of Viruses (ICTV) (ICTVdB, 2002). HAdV belong to the
genus Mastadenovirus, along with many of the other AdV that have mammals as their
host species. AdV genera are further divided into species (designated with a capital
letter) and subspecies (designated with a capital letter followed by a number). Species
and subspecies classification of the Mastadenovirus genus is based on a number of
characteristics including calculated phylogenetic distance, relative DNA homology,
restriction fragment profiles, percentage of GC content in the viral genome, oncogenicity
in rodents, growth phenotypes, host range, cross-neutralization, possibility of
recombination with other members, and genetic organization of the E3 transcription unit.
Species of AdV contain serotypes (given an Arabic number in the order they are
discovered), distinguishable by horse or rabbit reference sera. The serotypes are further
differentiated into genome types (or genomic variants) by restriction fragment length
polymorphism analysis (ICTVdB, 2002). Genome types are designated by a lower case
letter, and sometimes by a lower case letter followed by a number, following the serotype
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(for instance HAdV-7h, HAdV-7b, HAdV-3a2) (Li and Wadell, 1986). This naming
system is established within the field and is particularly useful for subspecies B1 HAdV,
and so has been chosen for use in this dissertation.
Several controversies and inconsistencies have arisen for the classification of
AdV. First, because HAdV have historically been studied more extensively than other
AdV, detailed classification criteria have been developed for HAdV. Serology to define
a new AdV “type” is the standard, and is reflected in the use of the term “serotype”.
However, this has led to questions regarding the classification of new AdV, including
many non-mammalian AdV for which infectious virus cannot be isolated. Additionally,
technological advances in the isolation and sequencing of AdV DNA have prompted a
reevaluation of the criteria by which AdV are classified. Use of nomenclature has been
inconsistent and incorrect (Jones et al., 2007; Walsh et al., 2009; Walsh et al., 2010),
despite clear guidelines from ICTV and established norms within the field.
Second, classification of AdV has historically placed emphasis on the host
species. For instance, previously all HAdV were classified separately from all simian
AdV, bovine AdV, etc. However, the emergence of new molecular and bioinformatics
tools has shown this classification scheme to be inappropriate. A greater emphasis is
now placed on genome sequence analysis, such that some simian AdV and bovine AdV
are classified with HAdV species (ICTVdB, 2002). However, the natural host species
remains important for the designation of AdV, as is obvious with “simian adenovirus”,
“bovine adenovirus”, “human adenovirus”, etc.
The dynamic field of AdV taxonomy likely will incorporate technological
advances in future classification and nomenclature.
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But, for the purpose of this

dissertation, AdV will be designated utilizing the most current ICTV guidelines and
established norms for the Adenoviridae Family.
Genome organization and transcription. The size and organization of the
genomes of viruses in the Family Adenoviridae vary among genera and species. For
instance, the E3 transcription unit is only present among the members of the genus
Mastadenovirus and some members of the genus Siadenovirus (Davison et al., 2003).
The smallest reported genome for a member of the Family Adenoviridae is 26,163 bp for
frog AdV 1 and the largest is 45,063 bp for fowl AdV D.

HAdV genomes are

consistently around 36,000 bp in size (ICTVdB, 2002).
AdV genomes contain inverted terminal repeats (ITR), which are important in
viral DNA replication (Davison et al., 2003). AdV genes are transcribed from both the l
and r strands and are organized into transcription units (Fig. 2). HAdV genomes, which
serve as the prototype for study, contain five early transcription units—E1A, E1B, E2,
E3, and E4—which are transcribed prior to the onset of viral DNA replication. Three
delayed early transcription units—IX, IVa2, and E2 late—are transcribed from promoters
separate from the early transcription units.

One late transcription unit—major late

(ML)—is efficiently transcribed from the major late promoter (MLP) after the onset of
viral DNA replication and primarily encodes structural genes.

In addition to the

transcription units, some AdV genomes encode virus associated RNA (VA RNA) genes.
In general, the AdV transcription units encode genes that serve related functions (Table
1). The organization and content of these transcription units varies among the members of
the Adenoviridae Family members (Davison et al., 2003).
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Figure 2. Genetic organization of the adenovirus transcription units. Early (red
arrows), delayed early (purple arrows), and late (blue arrows) adenovirus transcription
units are shown at their approximate location in the dsDNA genome. Forward arrows
(above) indicate transcription units encoded by the r strand, and reverse arrows (below)
indicate transcription units encoded by the l strand.
Approximate locations
corresponding to primers used for detection of major late promoter expression of ORF
E3-10.9K are indicated by black arrows (see Table 5 for more details). Adapted from
Akusjarvi, 2008.
Much of what is currently known regarding transcription of AdV genes comes
from work carried out on species C HAdV serotypes 2 and 5. Viral gene transcription is
temporally regulated. By definition, early genes are expressed prior to the onset of viral
DNA replication and late genes are expressed after viral DNA replication begins. Host
cell RNA polymerase II transcribes the viral genome transcription units while RNA
polymerase III transcribes the VA RNA genes (Pettersson and Roberts, 1986; Weinmann
et al., 1976). Alternative splicing produces multiple mRNA products from the AdV
transcription units (Fig. 2).
Expression of AdV transcription units is activated by the E1A viral proteins (Berk
et al., 1979; Nevins, 1981). E1A genes are the first genes transcribed once the viral
genome reaches the host cell nucleus upon infection (Nevins et al., 1979). Activation of
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Table 1. Adenovirus transcription units and encoded protein functions.
Transcription
unit

# of protein
products

Temporal
expression

General function of protein products

E1A

2

Early

Activation of transcription and host cell
induction of S phase

E1B

2

Early

Inhibition of apoptosis

E2 early

3

Early

DNA replication

E3

Varies

Early

Modulation of host response to
infection

E4

6

Early

Diverse, unrelated functions (including
induction of host cellular S-phase)

IX

1

Delayed early

Transcriptional activation, nuclear
reorganization, progeny virion stability

IVa2

1

Delayed early

Virion structural protein / MLP
activation

E2 late

3

Delayed early

DNA replication

Major late

13

Late

Production and assembly of progeny
virions

early transcription unit promoters is largely driven by the large E1A protein (Berk, 1986)
and is carried out through interaction of large E1A protein with host cellular transcription
factors (Berk, 2005; Liu and Green, 1994). The small E1A protein is responsible for
activation of transcription of the E2 early promoter (Bagchi et al., 1990; Phelps et al.,
1991). The MLP is the major controller of late mRNA expression for AdV. Although it
is active at early stages of infection, the MLP is over a hundred times more active after
viral DNA replication begins (Shaw et al., 1980). The MLP is activated by viral E1A
proteins along with host cellular transcription factors (Parks and Shenk, 1997), but the
mechanism by which the MLP activity depends on viral DNA replication is unknown.
However, there is evidence to suggest that changes in the viral chromatin that occur upon
12

viral DNA replication could play a role (Toth et al., 1992) as well as induction of a viral
transcription factor, protein IVa2, which is also involved in viral DNA packaging (PardoMateos and Young, 2004; Tribouley et al., 1994).

Late

coding

regions

are

transcribed as a single, large transcript of approximately 28 kb (Evans et al., 1977;
Nevins et al., 1978). The late transcript is spliced into distinct mRNAs that contain polyA tails and a 201 nucleotide untranslated region referred to as the tripartite leader (TPL)
(Berget et al., 1977; Chow et al., 1977). The TPL is generated by the splicing of three
short exons (leader 1, 2, and 3) to the 5’ end of a larger ORF (Berget et al., 1977). The
TPL is important for enhancing the translation of the ORFs to which it is spliced (Logan
and Shenk, 1984). While most products encoded in the ML transcription unit are
structural proteins, a region of the E3 transcription unit is expressed late for species C
HAdVs (Bhat and Wold, 1986).
Single cell replication cycle. Like other DNA viruses, the AdV replication cycle
is divided into two stages: early and late. By definition, the early stage occurs prior to
viral genome replication and the late stage after DNA replication begins. The early stage
of infection encompasses attachment, entry, uncoating, transport of the viral DNA to the
nucleus, and early viral gene expression. Upon viral genome replication, the late stage of
infection begins. At this stage, the viral late genes are expressed and progeny virions are
assembled and released from the host cell.
Attachment of the virion to the host cell is the first step in the AdV replication
cycle. This step is primarily mediated by the fiber protein on the surface of the AdV
virion (Lonberg-Holm et al., 1969). The host cell attachment receptor differs among
HAdV. In general, HAdV of species A, C, E and F interact with the coxsackievirus B
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and adenovirus receptor (CAR), a protein involved in the formation of cellular tight
junctions in polarized epithelial cells (Philipson and Pettersson, 2004). Species D HAdV
use sialic acid moieties as receptors (Arnberg et al., 2002). For species B HAdV, the
attachment receptor appears to vary with the serotype. Most of species B HAdVs use
complement regulatory molecule CD46 as an attachment receptor (Marttila et al., 2005),
but species B HAdV serotypes 3 and 7 bind to CD80 or CD86 (Short et al., 2004; Short et
al., 2006).
Concomitant with attachment of the AdV virion to the primary receptor via
interaction with the fiber protein, the penton base can also interact with host cellular
αvβ3/αvβ5 integrins. This interaction facilitates the internalization of the virions into
clathrin-coated vesicles and then into the host cell endosomal pathway (Mathias et al.,
1994; Patterson and Russell, 1983). The interaction of the virion with αvβ3/αvβ5 integrins
also induces the activation of PI3 kinases and Rho GTPases, leading to the alteration of
the host cytoskeleton (Li et al., 1998a; Li et al., 1998b). After entry of the virion into the
host cell endosomal pathway, the AdV particle is disrupted and releases peripentonal
hexons, protein IIIa, and protein VI from the virion, leaving a subviral particle consisting
of a hexon shell and associated viral core containing the viral genome and associated
proteins (Russell, 2009). The infected endosome/lysosome is then ruptured, allowing the
release of the hexon shell and virion core into the cytoplasm of the host cell. The hexon
shell is transported to the nuclear pore complex by way of microtubules (Dales and
Chardonnet, 1973; Greber and Way, 2006; Leopold et al., 2000; Mabit et al., 2002;
Suomalainen et al., 1999). Viral genome uncoating occurs at the nuclear pore complex,
where viral DNA and protein VII enter the nucleus (Greber et al., 1997).
14

Early gene expression begins upon entry of the viral DNA into the host cell
nucleus. The early genes (encoded in the E1A, E1B, E2, E3, and E4 transcription units)
prepare the host cell for the production of viral progeny. This function is accomplished
by (1) inducing the host cell to enter S phase, (2) protecting the host cell from antiviral
defenses while the virus replicates, and (3) synthesizing viral gene products necessary for
viral genome replication. As discussed in the “Genome organization and transcription”
section, the large and small E1A proteins activate the transcription of early genes.
Induction of the host cell to enter S phase is accomplished primarily by the E1A and E4
gene products. E1B, E3, and the VA RNA gene products are involved in protecting the
host cell from antiviral defenses.

Viral gene products necessary for viral genome

replication are encoded by the E2 transcription unit.
AdV genome replication requires three virus-encoded products—preterminal
protein (pTP), DNA polymerase (AdPol), and DNA binding protein (DBP)—and is
enhanced by three host-cell encoded products—transcription factor NFI, transcription
factor Oct-1, and type I topoisomerase NFII (de Jong et al., 2003). The first step of viral
genome replication is the formation of a heterodimer of pTP and the AdPol. This
heterodimer binds to the origin of DNA replication in the viral genome, located within
the ITR at the ends of the viral genome. DNA replication is then initiated by AdPol using
a strand-displacement mechanism that requires DBP. Synthesis of viral DNA is initiated
at one of the DNA termini and proceeds to the other end of the genome, with only one
strand serving as template. The complement to the second strand (the displaced strand) is
then synthesized. The displaced strand forms a panhandle structure consisting of the selfcomplementing ITR at either ends of the strand. This panhandle structure is recognized
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by the pTP/AdPol heterodimer and DNA synthesis proceeds (Lechner and Kelly, 1977;
Liu et al., 2003).
Late gene expression begins upon the initiation of viral genome replication. Late
genes (expressed from the ML transcription unit) encode products whose function is to
assemble progeny virions. The production of structural proteins that will encapsidate the
newly synthesized viral DNA and associated proteins that will aid in the assembly of the
progeny virions begins at this stage. Also during this time, the E3-11.6K/ADP encoded
in the E3 transcription unit of species C HAdVs is produced in large quantities (Tollefson
et al., 1992).
The assembly of progeny virions proceeds through a maturation process that
involves structural viral proteins as well as viral proteins that serve as scaffolds for the
newly assembled capsids. Progeny virions are assembled in the nucleus of the host cell
and have historically been thought to egress through lysis of the host cell. However,
evidence from species C HAdV suggests that egress is a more controlled process that is
mediated by viral factors. For species C HAdVs, the E3-11.6K/ADP is involved in the
efficient release of newly assembled viral particles from infected cells (Tollefson et al.,
1996b). It is unknown whether all members of the Adenoviridae Family use a similar
mechanism for egress.

Human adenoviruses
Discovery. HAdV were first discovered in 1953 by two separate research groups
(Hilleman and Werner, 1954; Rowe et al., 1953). The isolation of cells from adenoids of
young children led to the observation of a cytopathic agent that was capable of being
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passed to new cells. The agent was determined to be a virus, and was called “adenoid
degeneration agent” (Rowe et al., 1953). The same agent was isolated from respiratory
secretions of military recruits collected during an outbreak of pneumonitis at Fort
Leonard Wood, MO (Hilleman and Werner, 1954). The original isolation of AdV from
adenoid tissue led to their name (Enders et al., 1956).
Classification and taxonomy. All 51 recognized HAdV serotypes are currently
classified into six species (A-F) (Table 2) (ICTVdB, 2002). Species B is further divided
into subspecies B1 and B2 primarily on the basis of genomic DNA homology (Wadell,
1984). A new HAdV, tentatively designated HAdV-52, was recently described and
proposed to belong to an entirely new species G (Jones et al., 2007). The classification of
HAdV-52 along with the recognition of recently proposed new “types” remain tentative
until a review by the ICTV is complete (Jones et al., 2007).
Table 2. Classification of 51 recognized human adenovirus serotypes.1 Adapted
from ICTVdb, 2002.
Species Subspecies

Serotypes

A

12, 18, 31

B

1

3, 7, 16, 21, 50

2

11, 14, 34, 35

C

1, 2, 5, 6

D

8, 9, 10, 13, 15, 17, 19, 20, 23, 30, 32, 33, 36, 37, 38, 39, 42, 43,
44, 45, 46, 47, 48, 49, 51

E

4

F

40, 41

1

Candidate species G and its associated serotype 52 are not shown because of current
controversy regarding the use of this designation.
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Remarkable intraserotypic genetic diversity exists among HAdV. This diversity
has historically been documented through the use of restriction endonuclease digestion of
HAdV genomic DNA, but PCR and sequence analysis have also been important for
revealing this genetic variability. While essential viral proteins (including structural
proteins and proteins involved in viral replication and assembly) are largely conserved
among HAdV, the E1, E3, and E4 transcription units are not well conserved.
Additionally, “hotspots” of variability exist within the hexon and fiber genes and are
associated with major neutralizing epitopes on the virion (Bailey and Mautner, 1994;
Crawford-Miksza and Schnurr, 1996; Pichla-Gollan et al., 2006; Xia et al., 1994).
Homologous recombination among closely related HAdV serotypes is a recognized
mechanism contributing to AdV genetic diversity (Sambrook et al., 1980) and can lead to
the emergence of intermediate variants (Adrian and Wigand, 1986; Hierholzer et al.,
1980; Hierholzer and Rodriguez, 1981; Kajon and Wadell, 1996; Li and Wadell, 1988;
Wigand and Adrian, 1989).
Associated disease. HAdV are associated with upper respiratory tract infections,
lower respiratory tract infections, epidemic keratoconjunctivitis, conjunctivitis, acute
hemorrhagic cystitis, hepatitis, gastroenteritis, and myocarditis.

The unambiguous

association of HAdV serotypes with disease cannot be made, since route of infection and
immunocompetence of the host play a large role in the resulting clinical manifestation.
Some generalizations can be made about the different species, however. Species A
serotypes are associated with cryptic infections, although HAdV-31 is associated with
infant gastroenteritis and encephalitis (Adrian & Wigand, 1989; Schnurr et al., 1995).
Species B serotypes are associated with respiratory disease in children and adults,
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conjunctivitis, and urinary tract infections. Species C serotypes are associated with
respiratory disease in children under 5 years of age. Species D serotypes are associated
with epidemic keratoconjunctivitis and infections of immunocompromised individuals.
The only species E serotype, HAdV-4, is associated with respiratory infections and
conjunctivitis. Species F serotypes are associated with gastrointestinal infections.
Although some AdV induce tumors in rodent models, there is little evidence to
indicate a role for AdV in human tumor formation. Evidence suggestive of a role for
HAdV in the etiology of cancer comes from a recent study, which shows an association
between the detection of AdV DNA in neonatal blood and the development of acute
lymphoblastic leukemia, suggesting that prenatal AdV infection correlates with the
development of acute lymphoblastic leukemia (Gustafsson et al., 2007). However, a
more comprehensive study carried out by the same group shows no correlation between
the presence of AdV DNA in neonatal blood and acute lymphoblastic leukemia
(Honkaniemi et al., 2010). These conflicting findings leave the role of AdV in the
etiology of acute lymphoblastic leukemia currently unclear.
Treatment and vaccine. The lack of specific antivirals against AdV necessitates
the treatment of most infected individuals by symptomatic care.

However, in

immunocompromised patients, the risk of disseminated infection often requires
pharmaceutical interventions. No formally approved anti-adenoviral drugs are currently
available. However, small clinical studies of cidofovir and ribavirin show conflicting
results (Lenaerts et al., 2008). A vaccine against HAdV-4 and HAdV-7 was routinely
administered to U.S. military recruits from 1973 to 1996 (Gray et al., 2000; Top, 1975),
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and was effective at protecting this population from AdV outbreaks. No vaccine is
currently licensed for use in civilian populations.

Subspecies B1 human adenoviruses
Species B HAdVs are divided into two clusters of homology: subspecies B1 and
subspecies B2. Subspecies B1 includes the serotypes HAdV-3, -7, -16, -21, and -50 and
their genomic variants. Of these, HAdV-3 and HAdV-7 are most frequently isolated in
association with disease, while HAdV-16 and HAdV-21 are less frequently detected.
HAdV-50 was isolated from a 34-year old male with diarrhea who was hospitalized
because of AIDS (De Jong et al., 1999). HAdV-50 has not been isolated in association
with respiratory disease to date. Subspecies B2 includes the serotypes HAdV-11, -14, 34, and -35.

Subspecies B2 HAdVs are isolated in association with conjunctivitis,

urinary tract infections, and respiratory disease. Until the recent emergence of HAdV-14
into North America, the association of subspecies B2 HAdVs with severe respiratory
infections has been infrequent (Louie et al., 2008). Because the focus of this dissertation
is on the characterization of a subspecies B1 HAdV-specific ORF, the next sections focus
exclusively on the associated respiratory disease, epidemiology, and genetic diversity of
this subspecies.
Associated respiratory disease. HAdV-3, -7, -16, and -21 are associated with
acute lower respiratory infections of variable severity in pediatric and military recruit
populations. Symptoms range from mild to severe, and include sore throat, coughing,
rhinorrhea, wheezing, dyspnea, sinus tenderness, vomiting, abdominal pain, and diarrhea.
HAdV-3, -7, and -21 are associated with long-term pulmonary sequelae, including
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bronchiolitis obliterans and bronchiectasis in young children up to ten years after acute
infection and HAdV-associated pneumonia (Becroft, 1971; Herbert et al., 1977; Similä
et al., 1981). The viral factors contributing to the clinical manifestations of subspecies
B1 HAdV acute lower respiratory infections are unknown.
Epidemiology and genetic diversity. Subspecies B1 HAdVs have long been
recognized as important causative agents of epidemic outbreaks of respiratory tract
infections and pharyngoconjunctival fever (Becroft, 1971; Dudding et al., 1972; Gerber et
al., 2001; Herbert et al., 1977; Ryan et al., 2002; Spigelblatt and Rosenfeld, 1983; Wadell
et al., 1980). These outbreaks are most common in pediatric populations and military
recruits, and most frequently involve HAdV-7 and HAdV-3 and their genomic variants.
Military recruit populations are highly susceptible to HAdV respiratory infection.
Since soon after its discovery, HAdV has been recognized as the causative agent of the
majority of acute respiratory disease outbreaks among military recruits in the U.S.
(Grayston et al., 1959; Hilleman, 1957; McNamara et al., 1962). HAdV-7 and HAdV-4
(Species E) were the major causes of respiratory infections, and were chosen for use in
the vaccine administered to military recruits in the U.S. (Top, 1975). Since the cessation
of the vaccination protocols in 1996, HAdV infections re-emerged in the U.S. military
recruit populations (Gray et al., 2000; Metzgar et al., 2007; Ryan et al., 2002). The
extensive genetic diversity for some of the re-emerging HAdV serotypes, including
HAdV-3, HAdV-7, and HAdV-4 (Species E) has been described (Dickson, 2009; Kajon
et al., 2007).
In contrast to military recruit populations, surveillance of HAdV infections in
civilian populations is limited. Most available typing data are restricted to outbreaks of
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severe disease and fatal case reports. HAdV-3 and HAdV-7 and their genomic variants
are important causes of severe disease in pediatric populations. HAdV-3 respiratory
illness is associated with fatalities in pediatric patients (Hon et al., 2008; Kajon et al.,
1990; Kim et al., 2003). HAdV-7 is associated more frequently than HAdV-3 with
severe respiratory infections and fatal outcome (de Silva et al., 1989; Gerber et al., 2001;
Kajon et al., 1996; Kim et al., 2003).
Subspecies B1 HAdVs, in particular HAdV-7 and HAdV-3, show extensive
intraserotypic genetic diversity (Golovina et al., 1991; Kajon and Wadell, 1994; Li and
Wadell, 1986; Li and Wadell, 1988). Genomic variants of HAdV-7 and HAdV-3 are
often geographically restricted, but can spread to new geographic areas and take over as
the predominant circulating genomic variant (Erdman et al., 2002; Golovina et al., 1991;
Wadell et al., 1980). This phenomenon is called a genome type shift, and is correlated
with an apparent increased severity of associated disease (Erdman et al., 2002; Kajon and
Wadell, 1994; Kajon et al., 1996; Larranaga et al., 2000; Wadell et al., 1980; Wadell et
al., 1985).

The reason for this apparent increase in associated disease severity is

currently unknown.

Early region 3 transcription unit
The size and coding content of the E3 transcription unit varies considerably
among the AdV (Davison et al., 2003). The E3 transcriptin unit encodes non-structural
products that are dispensable for growth in cell culture, hamster lungs, or cotton rats
(Ginsberg et al., 1989; Morin et al., 1987). The E3 transcription unit is transcribed from
the r strand of the double-stranded DNA viral genome, and is the only region of the
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HAdV genome that encodes integral membrane proteins (Wold et al., 1995). The E3
transcription unit is only present in the genomes of members of the genus
Mastadenovirus and some members of the genus Siadenovirus (Davison et al., 2003).
This transcription unit is thought to have arisen independently within these two genera, or
to represent an ancient locus of rapid gene evolution that has been subsequently lost in
the Atadenovirus and Aviadenovirus genera (Davison et al., 2003). The flanking ORFs
present within the HAdV E3 (E3-12.5K and E3-14.7K) are distantly related and are
hypothesized to have arisen by a gene duplication event early in Mastadenovirus
evolution (Davison et al., 2003).
The analysis of the E3 transcription unit has been undertaken for mouse AdV
(Beard et al., 1990; Beard and Spindler, 1995; Beard and Spindler, 1996; Cauthen et al.,
1999; Cauthen and Spindler, 1999), canine AdV (Dragulev et al., 1991; Linné, 1992),
bovine AdV (Belák et al., 1986; Esford and Haj-Ahmad, 1994; Evans et al., 1998;
Idamakanti et al., 1999; Mittal et al., 1993), porcine AdV (Kleiboeker, 1994; Reddy et al.,
1995; Tuboly and Nagy, 2000), and ovine AdV (Vrati et al., 1995). However, functional
roles for E3-encoded protein products have only been determined for HAdV.

The

remainder of this section will focus on the HAdV E3 transcription unit.
Diversity of E3 among human adenoviruses. No other HAdV transcription unit
is as heterogeneous as E3 (Chroboczek et al., 1992). ORFs E3-12.5K, E3-19K, E310.4K, E3-14.5K, and E3-14.7K are highly conserved among HAdV species A-F (Fig. 3).
Species F is the only HAdV species that does not encode ORF E3-12.5K. Species A and
F do not encode ORF E3-19K. Between the highly conserved ORFs E3-19K and E310.4K, species-specific E3 ORFs are encoded.
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For species C HAdVs, this region

contains ORF E3-11.6K. For species B HAdV, ORFs E3-20.1K and E3-20.5K are
encoded. Subspecies B1 HAdVs, but not subspecies B2 HAdVs, additionally encode
ORF E3-10.9K in the species-specific region.

Figure 3. Comparison of the E3 transcription unit coding capability for human
adenoviruses of species A-F. E3 ORFs are indicated for a representative member of
each HAdV species A-F. Adapted from Burgert and Blusch, 2000.

Transcription and splicing. Our knowledge of the transcription and splicing of
the E3 transcription unit has come from studies of HAdV-2 and HAdV-5. The E3
promoter is activated by AdV E1A protein and tumor necrosis factor α (TNFα)
(Deryckere and Burgert, 1996; Korner et al., 1992; Kornuc et al., 1990). The E3 mRNAs
and splicing for HAdV-2 and HAdV-5 have been characterized extensively, but E3
mRNAs for other serotypes belonging to other species of HAdV have been neglected
(Wold et al., 1995). For HAdV-2 and HAdV-5, nine mRNAs are produced from the E3
transcription unit. These are alternatively spliced and polyadenylated at either the E3A or
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E3B polyadenylation sites (Wold et al., 1995). Limited analysis of HAdV-3 E3 mRNAs
show that exact RNA splice junctions are not conserved between HAdV-2 and HAdV-3,
although mRNAs corresponding to most HAdV-3 E3 ORFs can be detected (Signäs et
al., 1986).
Conserved E3 proteins encoded by HAdV genomes. The characterization of
HAdV E3 proteins has largely focused on species C HAdV-encoded proteins. The E3
proteins that are highly conserved among HAdV and are expressed in infected cells
include E3-12.5K (Hawkins and Wold, 1992), E3-19K (Persson et al., 1980; Ross and
Levine, 1979), E3-10.4K (Tollefson et al., 1990), E3-14.5K (Tollefson et al., 1990), and
E3-14.7K (Persson et al., 1978; Tollefson and Wold 1988; Wang et al., 1988). Functions
are assigned to all these proteins except E3-12.5K.
The E3-19K protein blocks MHC class I transport to the plasma membrane,
interfering with antigen presentation and T-cell recognition of infected cells (Andersson
et al., 1985; Andersson et al., 1987; Burgert and Kvist, 1985; Burgert et al., 1987). In
animal models, the immunomodulatory role for E3-19K has been confirmed; cotton rats
infected with wild type HAdV-5 show less immunopathology than those infected with
HAdV-5 mutants lacking the E3-19K (Ginsberg et al., 1989). HAdV serotypes from
species B, D, and E but not A or F express the conserved E3-19K, and the protein
modulates the expression of MHC class I like its counterpart for species C HAdV (Pääbo
et al., 1986)
E3-10.4K/RIDα and E3-14.5K/RIDβ are referred to collectively as the receptor
internalization and degradation (RID) complex, and are involved in the inhibition of host
cell apoptosis through several mechanisms. First, RID down-regulates proapoptotic cell
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surface receptors, including Fas, TRAILR1, and TRAILR2. Downregulation of these
receptors protects HAdV infected cells from apoptosis (Benedict et al., 2001; Elsing and
Burgert, 1998; Shisler et al., 1997; Tollefson et al., 1998; Tollefson et al., 2001). Second,
RID inhibits TNF-α-induced arachidonic acid release by blocking the translocation of
cytosolic phospholipase A2 to host cell membranes, which prevents TNF-α-mediated
apoptosis (Dimitrov et al., 1997; Krajcsi et al., 1996).

Third, RID inhibits NF-κB

activation induced by interleukin-1 and TNF-α by inhibiting NF-κB translocation to the
nucleus (Friedman and Horwitz, 2002).
E3-14.7K, unlike other E3 proteins, is not an integral membrane protein. E3-14.7K
is a cytoplasmic and nucleoplasmic protein that functions primarily in the inhibition of
TNF-α-induced apoptosis of host cells (Gooding et al., 1990). However, E3-14.7K
accomplishes this function through a mechanism independent of RID (Horton et al.,
1991).
Species-specific E3 proteins.

Several species-specific E3 ORFs have been

shown to be expressed in infected cells. These include species C HAdV E3-11.6K,
species C HAdV E3-6.7K, species B HAdV E3-20.5K, species D HAdV E3-49K, and
speices E HAdV E3-30K (Fig. 3). Of these, functions have been assigned only to E311.6K and E3-6.7K.
E3-6.7K localizes primarily to the ER and interacts with the RID complex to
down-regulate TRAIL2 receptors (Benedict et al., 2001). Additionally, E3-6.7K represses
apoptosis of host cells by maintaining cytosolic Ca2+, similar to host cellular protein Bcl2 (Moise et al., 2002).
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E3-11.6K is the most extensively characterized species-specific E3 ORF. This
ORF encodes the ADP. E3-11.6K/ADP is expressed at early stages of infection like
other E3 proteins, but expression is greatly amplified at late stages of infection, primarily
as a result of increased transcription from the AdV MLP (Tollefson et al., 1992). The
protein is both N- and O-glycosylated (Scaria et al., 1992; Tollefson et al., 2003),
palmitoylated at the cytoplasmic tail (Hausmann et al., 1998), and localizes primarily to
the nuclear envelope (Scaria et al., 1992). HAdV-2 and HAdV-5 E3-11.6K/ADP deletion
mutants have a small plaque phenotype, kill cells more slowly, and retain progeny virions
in the nucleus compared to wild-type viruses that produce virions that exit the host cell
efficiently (Tollefson et al., 1996a). Furthermore, the E3-11.6K/ADP is required for the
efficient release of progeny virions from infected cells (Tollefson et al., 1996b). Directed
mutation of the E3-11.6K/ADP shows that, in general, (1) the lumenal domain is
important for the efficient transit of E3-11.6K/ADP through the trans-Golgi network and
into the nuclear envelope, (2) glycosylation seems to stabilize E3-11.6K/ADP, (3)
deletion of the transmembrane domain results in aggregation of E3-11.6K/ADP in the
cytoplasm and loss of function, and (4) the cytoplasmic-nucleoplasmic domain is
important for localization (Tollefson et al., 2003). The mechanism of action for E311.6K/ADP is unknown.

However, in yeast two-hybrid screens and glutathione-S-

transferase (GST)-pull down assays, the C-terminus (cytoplasmic-nucleoplasmic domain)
of E3-11.6K/ADP interacts with the human protein MAD2B, a protein implicated in
mitosis control, error-prone DNA synthesis promotion, and cell-cell interactions (Ying
and Wold, 2003). However, the importance or functional significance of this interaction
is unknown.

27

The E3-20.5K protein is expressed in HAdV-3 and HAdV-7 infected KB cells
(Hawkins and Wold, 1995a). The protein is synthesized throughout the viral replication
cycle (Hawkins and Wold, 1995a). Treatment with glycosidases shows that the protein is
both N- and O-glycosylated (Hawkins and Wold, 1995b). Although E3-20.5K protein
was hypothesized to cause MHC class I retention in the ER because of its structural
similarities to E3-19K, no evidence thus far supports this hypothesis (Hawkins and Wold,
1995b), and a function for this protein is currently unknown.
A549 cells infected with species D HAdV serotypes 8, 9, 15, 19a, and 37 express
E3-49K

(Blusch et al., 2002).

The E3-49K protein is detected at early stages of

infection, and expression continues throughout the viral replication cycle. The E3-49K
protein contains N- and O-linked glycans, and the protein localizes primarily to the transGolgi network and early endosomes. However, some plasma membrane localization is
detected in infected cells expressing high levels of the E3-49K protein. The function of
the E3-49K protein is currently unknown (Windheim and Burgert, 2002).
HAdV-4, the sole member of the species E HAdV, encodes ORF E3-30K. The
E3-30K protein is expressed at early stages of infection but is amplified at late stages of
infection, similar to species C HAdV E3-11.6K/ADP. The protein is N-glycosylated and
localizes primarily to the nuclear membrane and endoplasmic reticulum. A function has
not been assigned to the E3-30K protein (Li and Wold, 2000).
Role of E3 in adenovirus pathogenesis. The E3 transcription unit is dispensable
for virus growth in cell culture (Lewis et al., 1974). However, the E3 transcription unit
plays an important role in AdV pathogenesis. Both cotton rats (Sigmodon hispidus) and
mice are used in studies investigating the role of E3 in the pathogenesis of respiratory
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infections. Intranasal inoculation of cotton rats or mice with HAdV-5 E3 deletion mutant
viruses results in more extensive pathology compared to wild-type viruses (Ginsberg et
al., 1989; Sparer et al., 1996). Additionally, E3-deleted AdV vectors administered to
cystic fibrosis patients induce a major inflammatory response (Crystal et al., 1994),
further supporting the role of the E3 transcription unit in AdV-pathogenesis.

ORF E3-10.9K of subspecies B1 human adenoviruses
ORF E3-10.9K is encoded only in subspecies B1 HAdV genomes. This ORF is
absent in subspecies B2 HAdV genomes. In HAdV-11 and HAdV-35, of subspecies B2
HAdV, the lack of ORF E3-10.9K is postulated to account for their unique association
with persistent infection of the renal epithelia (Flomenberg et al., 1988; Mei and Wadell,
1992).

ORF E3-10.9K shows extensive intraserotypic diversity.

Predicted protein

products range in size from 4.8 kDa to 10.9 kDa, with some genomic variants of HAdV-7
and HAdV-3 lacking the ability to encode a protein because of a mutated start codon.
For ease of discussion herein, the ORF will be referred to as ORF E3-10.9K regardless of
the size of the encoded product. For instance, ORF E3-10.9K of HAdV-3p is predicted to
encode a polypeptide of 9 kDa, ORF E3-10.9K of HAdV-7p is predicted to encode a
polypeptide of 7.7 kDa, and ORF E3-10.9K of HAdV-7h is predicted to encode no
polypeptide.
Intraserotypic diversity. The intraserotypic polymorphism of ORF E3-10.9K
was first noted when examining an Argentinean isolate of HAdV-7h (Kajon and Wadell,
1996). HAdV-7h was the predominant circulating genome type of HAdV-7 in South
America, and was the sole genomic variant circulating after replacing HAdV-7c in 1986
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(Kajon and Wadell, 1994). Genome type HAdV-7h attracted intense interest because of
its association with severe acute respiratory infections of children (Kajon et al., 1994;
Murtagh et al., 1993). In a search for a molecular basis for the apparent increased
severity of disease associated with HAdV-7h infection, sequencing of the E3
transcription unit revealed the absence of an E3 ORF found in HAdV-7p, referred to as
ORF E3-7.7K. This difference was because of an ATGÆATT mutation, eliminating the
putative start codon (Kajon and Wadell, 1996).
A more thorough sequence examination of this ORF was carried out on 55
laboratory strains and field isolates representing all subspecies B1 HAdV serotypes and
many HAdV-3 and HAdV-7 genome types (Kajon et al., 2005). This study documented
extensive intraserotypic variation of ORF E3-10.9K for subspecies B1 HAdVs, and
identified eight sequence profiles (SP1-SP8) for this coding region (Fig. 4). Additionally,
RT-PCR showed the expression of mRNAs corresponding to ORF E3-10.9K in cells
infected with HAdV-16p, HAdV-3p, HAdV-7p, HAdV-7b, and HAdV-7h (Kajon et al.,
2005).
Illegitimate recombination as a mechanism generating variability in ORF
E3-10.9K. Because the striking variation of ORF E3-10.9K among genomic variants of
the same serotype is unique among HAdV, it is referred to as a “hot spot” of mutations
(Kajon et al., 2005). Sequence analysis suggests a slippage/misalignment model for the
generation of the ORF E3-10.9K polymorphism. In the slippage/misalignment model, a
transient dissociation of the DNA duplex during replication results in a slipped-strand
mispairing between two regions having short homologies (Kunkel, 1990). One of these
repeats is deleted along with the intervening sequences in the daughter strand.
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Figure 4. Nucleotide sequence alignment of ORF E3-10.9K sequence profiles (SP18). Start codon (black underline), stop codons (red highlight), single base mutations
(yellow highlight), palindromic motifs (blue box), inverted repeats (green highlight), and
polypurine/polypyrimidine runs (*) are indicated. Adapted from Kajon et al., 2005.
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Palindromic sequence motifs, inverted repeats, polypurine/polypyrimidine runs, single
base mutations in close proximity to deletion junctions, and loss of one of two short
direct repeat sequences at or near deletion junctions are observed in ORF E3-10.9K
polymorphism and are consistent with the slippage/misalignment model (Kajon et al.,
2005) (Fig. 4).

Viroporins
The term viroporin describes a class of viral proteins encoded by diverse virus
families. These proteins are small, highly hydrophobic, involved in the efficient release
of progeny virions from infected cells, and are capable of permeabilizing membranes to
small molecules and ions (Carrasco, 1995; Gonzalez and Carrasco, 2003). Viroporins
encoded by different virus families have similar functions and features, but share little
sequence similarity. The term viroporin arose from the initial observation that, during
infection of host cells by viruses, there were specific times during which infected cells
became permeable to translation inhibitors (Carrasco, 1978).

The search for viral

products involved in this process led to the discovery that the poliovirus 2B protein is
capable of inducing membrane permeability in an E. coli expression system (Aldabe et
al., 1996). Many virus families encode proteins similar to poliovirus 2B in both features
and functions (Antoine et al., 2007; Bodelon et al., 2002; Daniels et al., 2006; Han and
Harty, 2004; Madan et al., 2005; Madan et al., 2007; Nieva et al., 2003). Most of the
studies of viroporins investigate the biochemical basis of their permeabilizing ability.
Aromatic amino acids in or near a hydrophobic domain, stretches of basic amino acids,
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and the formation of homo-oligomers can all contribute to the permeabilizing activity of
the viroporins (Agirre et al., 2002; Sanz et al., 2003).

Non-enveloped DNA virus progeny egress
Non-enveloped DNA viruses replicate and assemble in the host cell nucleus.
Therefore, progeny virions must pass the nuclear envelope as well as the plasma
membrane to exit cells. A long-held assumption is that non-enveloped DNA viruses exit
host cells through a non-specific lytic mechanism.

However, recent studies have

revealed a more controlled process of non-enveloped DNA virus egress. Besides species
C HAdV E3-11.6K/ADP, several other proteins expressed by non-enveloped DNA
viruses play a role in progeny virus egress. Two members of the Family Polyomaviridae
(circular double-stranded DNA genome), JC virus and simian virus 40 (SV40), encode
proteins that promote virion release. For JC virus, a small hydrophobic protein called
agnoprotein contributes to virion release, and is proposed as a viroporin (Suzuki et al.,
2010). Agnoprotein promotes virion release, possibly through changes in membrane
permeability and alterations of intracellular Ca2+ homeostasis (Suzuki et al., 2010). In the
closely related SV40, a viral structural protein, VP3, is implicated in progeny virion
release and is also proposed as a viroporin (Daniels et al., 2006). Further studies are
necessary to fully elucidate the mechanism of action of these proteins. But these limited
investigations suggest a dynamic and controlled process for non-enveloped DNA virus
progeny release.
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Gaps in current knowledge
Most of what is known about the molecular biology of HAdV is based on
extensive studies of species C HAdV serotypes 2 and 5. Although subspecies B1 HAdVs
are important causes of severe respiratory disease in pediatric and military populations,
studies of their molecular biology have been neglected. Fundamental features of the viral
replication cycle are likely conserved among the HAdVs, but unique features of the
subspecies B1 HAdV genomes could contribute to their distinct pathogenesis. For this
reason, targeted studies of unique subspecies B1 HAdV genes and molecular biology are
justified. Because of its proposed role in virus-host interactions and its extensive diversity
among HAdV, the E3 transcription unit is a logical choice for initial examination of
changes in this region and the impact of these changes on viral pathogenesis.
Questions also remain regarding the genome type shifts that occur over time.
Beyond observations that these genome type shifts occur, little work has been done to
understand the basis of the apparent increased severity of disease associated with these
shifts. A viral genomic basis for this phenomenon is likely, so understanding subspecies
B1 HAdV genetic diversity and its implications for viral fitness and virulence is
important.

The unique genomic features of subspecies B1 HAdV that emerge as

predominant circulating genome types must be investigated to begin to understand how
genetic changes impact viral virulence and fitness.
Gaps also remain in our understanding of the late stages of non-enveloped DNA
virus replication cycles. My work addresses this in Chapter 6. Enveloped virus budding
is relatively well characterized, but a similar effort has not been put forth to understand
the mechanisms by which non-enveloped viruses egress from infected cells. This lack of
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attention is likely to the result of the well-accepted assumption that most non-enveloped
viruses, including adenoviruses, simply lyse cells at the end of infection through an
uncontrolled mechanism. However, studies of species C HAdV E3-11.6K/ADP and
putative viroporins expressed by polyomaviruses suggest a more controlled mechanism
for non-enveloped virus egress. The late stage of the non-enveloped virus replication
cycle is a relatively unexplored area of virology.

A better understanding of non-

enveloped virus egress could lead to new strategies for the development of antivirals.
Finally, the ORF E3-10.9K polymorphism appears to represent a unique case of
extensive intraserotypic diversity of an E3 ORF. Questions remain such as: What is the
function of ORF E3-10.9K-encoded polypeptides?

What is the impact of the

polymorphism for the virus life-cycle? What selective pressures might be driving the
evolution of this ORF? What is the impact of the polymorphism for virus fitness and
virulence?

The work described hereafter was undertaken to begin to answer these

questions, to drive the field of adenovirology beyond a focus on species C HAdVs, and to
uncover important information regarding the impact of genetic variation among
subspecies B1 HAdVs for virus fitness and virulence.
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Chapter 3: Materials and Methods

Cells, media, and growth conditions
A549 cells (ATCC #CCL-185) were grown in 8% (v/v) newborn calf serumsupplemented Eagle Minimum Essential Medium (EMEM) (A549 Growth Medium).
Infected cells were maintained in 2% (v/v) newborn calf serum-supplemented EMEM
(A549 Infection Medium). HeLa T-RExTM cells (Invitrogen, Carlsbad, CA) were grown
according to manufacturer’s instructions in 10% (v/v) fetal bovine serum-supplemented
EMEM and 5 μg/mL blasticidin (HeLa T-RExTM Growth Medium). HeLa T-RExTM cells
stably transfected with 4/TO enhanced green fluorescent protein (EGFP) expression
plasmids were maintained in HeLa T-RExTM Growth Medium supplemented with 100
μg/mL zeocin (HeLa T-RExTM Selection Medium), and expression of fusion proteins was
induced with HeLa T-RExTM Selection Medium supplemented with 1 μg/mL tetracycline
(HeLa T-RExTM Induction Medium). Cells were grown at 37°C with 5% CO2.

Viruses, stocks, infections, and viral DNA
Viruses used for this study included the prototype strains of serotypes 3, (strain
GB; Rowe et al., 1953), 7 (strain Gomen; Berge et al, 1955), and 16, (strain Ch.79;
Murray et al., 1957), and HAdV-7 field strains KCH4 (Wadell et al., 1980), Argentina
87-922 (Kajon et al., 1996), and NHRC 611 (courtesy of Department of Respiratory
Diseases Research, Naval Health Research Center). These viruses represent genome
types 3p, 7p, 16p 7b, 7h and 7d2, respectively, which encode orthologs of ORF E3-10.9K

36

(Kajon et al., 2005). Virus stocks were grown in A549 cells, harvested by three freezethaw cycles and clarified of cell debris by centrifugation at 300 x G. Infectious virus
titers were determined by standard plaque assay on A549 cell monolayers under an
agarose/medium overlay. AdV infections of A549 cell monolayers were carried out at a
multiplicity of infection (MOI) of 1, 5 or 10 plaque forming units (PFU) per cell. Cell
medium was aspirated, viral inoculum was added, and flasks were incubated at 37˚C with
5% CO2 for 1 hour with periodic rocking. For experiments requiring the inhibition of
viral DNA replication, medium was replenished with A549 Infection Medium containing
40 µg/mL Cytosine β-D-arabinofuranoside hydrochloride (Ara-C) (Sigma, St. Louis,
MO). Inhibition of viral DNA replication was maintained by supplementing infection
medium with an additional 40 µg/mL of Ara-C at 8, 24, and 36 h pi.
Intracellular viral DNA was isolated from infected cell monolayers by an
established method (Kajon and Erdman, 2007).

Bacterial strains
Bacterial strains JM109 (Promega, Madison, WI) and TOP10 (Invitrogen,
Carlsbad, CA) were used for routine molecular cloning.

ECOS-21 cells (Yeastern

Biotech Co., Taiwan) were used for expression of GST-tagged fusion proteins.
BW25113 (Datsenko and Wanner, 2000) and SW105 (Warming et al., 2005) strains were
obtained from Dr. Katherine Spindler (University of Michigan) and were used for
recombination-based mutagenesis of the HAdV-3p genome.
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Antibodies
Antibodies used in immunofluorescence microscopy, Western blot analysis, and
immunoprecipitations included mouse anti-HA (MMS-101R, Covance, Princeton, NJ),
mouse anti-EGFP (JL-8, Clontech, Mountain View, CA), mouse anti-calnexin (Ab2798,
Abcam, Cambridge, MA), mouse anti-Golgin97 (A21270, Molecular Probes, Carlsbad,
CA), mouse anti-58K Golgi protein (Ab6284, Abcam, Cambridge, MA), rabbit anti-HA
conjugated agarose beads (Ab27029, Abcam, Cambridge, MA), goat anti-GST
(27457701, GE Healthcare Biosciences, Pittsburgh, PA), HRP-conjugated rabbit antigoat (305-035-003, Jackson ImmunoResearch, West Grove, PA) and HRP-conjugated
goat anti-mouse (115-035-003, Jackson ImmunoResearch, West Grove, PA).

DNA sequencing and alignment software
DNA sequences were generated at the DNA Research Services core facility,
University of New Mexico. Sequences were analyzed using Lasergene version 7.0.0
(DNASTAR, Inc., Madison, WI).

Protein structural predictions
Hydrophobicity plots were generated using the Kyte-Doolittle algorithm
implemented in Protean software (Lasergene version 7.0.0, DNASTAR, Inc., Madison,
WI). N-glycosylation and O-glycosylation sites were predicted using the web-based
NetNGlyc

1.0

(http://www.cbs.dtu.dk/services/NetNGlyc/)

and

NetOGlyc

3.1

(http://www.cbs.dtu.dk/services/NetOGlyc/) (Julenius et al., 2005). Protein topology was
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predicted using the web-based TopPred prediction program (http://mobyle.pasteur.fr/cgibin/portal.py?form=toppred) (Claros and von Heijne, 1994; von Heijne, 1992).

Molecular cloning of ORF E3-10.9K orthologs for mammalian and bacterial expression
Viral DNA was used as template for PCR-based mutagenesis of ORF E3-10.9K.
Primers used are listed in Table 3. For the the ORF E3-10.9K orthologs encoding the 7.7
kDa, 9 kDa, and 10.9 kDa proteins, first round PCR to amplify ORF E3-10.9K was
conducted using Hashido forward and Hashido reverse primers (Hashido et al., 1999)
(Table 3). A second round of PCR was conducted to add a Kozak consensus sequence,
Table 3. Molecular cloning primers
Mammalian Expression Plasmid Cloning Primers
Hashido forward
5’-CAAAAAGGTGATGCATTACC-3’
Hashido reverse

5’-TGTTCACCATACTGTAAGA-3’

10.9K up Kozak HindIII

5’-TTATAAGCTTGCCGCCACCATGATATTGTTTC-3’

7.7K down BamHI EGFP 5’-CGGACGGATCCTCATAGGAG-3’
10.9K/9K BamHI EGFP

5’-CATGAGGATCCTTGATTTCATTCAG-3’

4.8K up

5'-TTATAAGCTTATGATATTGTTTC-3'

4.8K down

5'- TTATAAGCTTATGATATTGTTTC-3'

Bacterial Expression Plasmid Cloning Primers
HAdV-16p/7p/7b up
5'-TTATAAGCTTATGATATTGTTTC-3'
HAdV-16p/3p down

5'-AGGATCCTTGATTTCATTCAG-3'

HAdV-7p down

5'-GGACGGATCCTCATAGG-3'

HAdV-7b down

5'- TTATAAGCTTATGATATTGTTTC-3'
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upstream HindIII and downstream BamHI restriction endonuclease recognition
sequences, and to mutate the stop codon using the following primers: 10.9K up Kozak
HindIII, 7.7K down BamHI EGFP, and 10.9K/9K BamHI EGFP (Table 3). High fidelity
PCR was carried out using iProof High Fidelity DNA Polymerase (Promega, Madison,
WI) following the manufacturer’s recommended cycling conditions. Second round PCR
products were purified using Micropure EZ columns (Millipore, Bedford, MA) and
Microcon columns (Millipore, Bedford, MA) following the manufacturer’s recommended
protocol, digested with BamHI and HindIII, and cloned into pEGFP-NI vector (Clontech,
Mountain View, CA).
For cloning of the ORF E3-10.9K ortholog encoding the 4.8 kDa protein, first
round PCR was performed using the primers 4.8K up and 4.8K down to mutate the stop
codon and generate downstream BamHI and upstream HindIII restriction endonuclease
recognition sites (Table 3). High fidelity PCR was carried out using iProof High Fidelity
DNA Polymerase (Promega, Madison, WI) following the manufacturer’s recommended
cycling procedure.

The PCR product was purified using Micropure EZ columns

(Millipore, Bedford, MA) and Microcon columns (Millipore, Bedford, MA), and cloned
into intermediate cloning vector pCR2.1 TOPO TA (Invitrogen, Carlsbad, CA) according
to the manufacturer’s recommendations. Positive bacteria colonies were identified by
colony-based PCR and plasmid DNA was isolated using GenElute Plasmid Prep kit
(Sigma, St. Louis, MO). The ORF encoding 4.8 kDa was then subcloned into pEGFP-N1
vector (Clontech, Mountain View, CA) using BamHI and HindIII sites.
Finally, EGFP-tagged ORF E3-10.9K orthologous genes were cloned into
pCDNA 4/TO vector (Invitrogen, Carlsbad, CA) using convenient HindIII and NotI
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restriction endonuclease recognition sequences. Plasmids generated were referred to as
pCDNA 4/TO 4.8 kDa-EGFP, pCDNA 4/TO 7.7 kDa-EGFP, pCDNA 4/TO 9 kDaEGFP, and pCDNA 4/TO 10.9 kDa-EGFP.
For generation of bacterial expression constructs, the above procedures were
carried out with the following changes. The primers used included HAdV-16p/7p/7b up,
HAdV-16p/3p down, HAdV-7p down, and HAdV-7b down (Table 3).

Primers

introduced mutations to eliminate the start codon and add upstream BamHI and
downstream SalI restriction endonuclease sites for subsequent cloning. Subcloning of the
mutated inserts into pGEX-5X-1 (Amersham Biosciences, Piscataway, NJ) bacterial
expression vector was accomplished by digestion with BamHI and SalI.

Bacterial

expression constructs were maintained in JM109 E. coli (Promega, Madison, WI) and
transformed into ECOS-21 E. coli (Yeastern Biotech Co., Taiwan) for inducible
expression experiments. Plasmids generated were referred to as pGEX-4.8K, pGEX7.7K, pGEX-9K, and pGEX-10.9K.
All constructs were confirmed by sequencing at the DNA Research Services core
facility, University of New Mexico.

RNA isolation
A549 cells were infected with subspecies B1 HAdVs encoding various ORF E310.9K orthologs (Table 4) at a MOI of 5 PFU/cell. At 8 and 24 h pi, total RNA was
extracted using the RNaqueous kit (Ambion, Austin, TX) following manufacturer’s
instructions. RNA was treated with TURBO DNA-free kit (Ambion, Austin, TX) to
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remove contaminating DNA. Elimination of DNA was confirmed by absence of visible
bands by PCR using total RNA as template (data not shown).

Table 4. Subspecies B1 HAdVs and the size of the protein encoded by their
associated ORF E3-10.9K orthologs
Virus

Size of protein encoded by
ORF E3-10.9K ortholog

HAdV-16p strain Ch. 79

10.9 kDa

HAdV-3p strain GB

9 kDa

HAdV-7p strain Gomen

7.7 kDa

HAdV-7d2 strain NHRC 611

4.8 kDa

HAdV-7b strain KCH4

4.8 kDa

HAdV-7h strain Argentina 87-922

NULL

RT-PCR
RNA (1 µg) and random decamers were used to generate cDNA using the
RETROscript kit (Ambion, Austin, TX) in a 20 µL total volume following the
manufacturer’s recommended protocol. The cDNA product (1 µL) was amplified by
PCR in a total volume of 50 µL of PCR mix including 1X GoTaq Buffer, 1 unit of GoTaq
polymerase, 0.2 mM dNTPs, 1.5 mM MgCl2, and 25 pmol of each primer (Promega,
Madison, WI). The primers used for RT-PCR are described in Table 5. The reactions
were heated to 95˚C for 5 min for the initial denaturation step followed by 34 cycles of
the following: 94˚C for 30 sec, annealing temperature for 30 sec, and 72˚C for 30 sec.
Annealing temperature used for each primer pair was 2˚C lower than the lowest Tm for
the primer pair (Table 5). Cycling was followed by a final extension at 72˚C for 7 min at
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the end of which the reaction was kept at 4˚C until analysis.

PCR products were

analyzed by agarose gel electrophoresis in Tris-Borate-EDTA buffer. PCR products were
visualized after ethidium bromide staining with a Universal Hood II/Gel Doc XR Camera
and Quantity One software (Bio-Rad, Hercules, CA).

Cloning and sequencing of RT-PCR MLP products
RT-PCR products of interest were gel purified and cloned using the pCR2.1
TOPO TA cloning kit (Invitrogen, Carlsbad, CA). Products were sequenced at the DNA
Research Services core facility, University of New Mexico. Consensus sequences for
each product were deposited in Genbank (Accession numbers: GU951413-GU951425).

Membrane fractionation
A549 cells were infected at a MOI of 10 PFU/cell. At 48 h pi, cells were washed
twice in 1X PBS and 1 mL hypotonic buffer (40 mM HEPES, 4 mM EDTA, 4 mM
EGTA, 10 mM DTT, 1 mM sodium vanadate, 1 mM PMSF, complete mini protease
inhibitor cocktail (Roche, Basel, Switzerland)) was added. Cells were scraped from the
dish, transferred to 1.5 mL tube and incubated on ice for 30 min. After incubation,
samples were sonicated 3 times for 2 sec pulses and centrifuged at 100,000 x G for 1 hour
at 4°C in a swinging bucket rotor ultracentrifuge. After centrifugation, the supernatant
(cytosolic fraction) was collected, the pellet was resuspended in 1 mL of 1 X lysis buffer
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Table 5. Primers for RT-PCR
Primer name

Sequence (5’-3’)

Tm (°C)

Nucleotide
position1

Corresponding
gene/coding region

E3-10.9K forward

GTTTCAATCAAATACC

43.9

29796-29811

E3-9 kDa glycoprotein

E3-10.9K reverse

CTAATCATAGGAGAATAG

42.5

29973-29990

E3-9 kDa glycoprotein

E3-10.9K reverse Tm60

GGGACGACTAATCATAGGAGAATAG

61.8

29973-29997

E3-9 kDa glycoprotein

TPL3 forward

CAGTCGCAATCGCAAG

60.3

9548-9563

Tripartite leader 3

Hexon reverse

GGTCTGTTAGGCATGGC

59.1

19353-19369

L3/Hexon protein

RIG/s15 forward

TTCCGCAAGTTCACCTACC

62.6

N/A

Small ribosomal subunit
rig/S152

RIG/s15 reverse

CGGGCCGGCCATGCTTTACG

76.9

N/A

Small ribosomal subunit
rig/S152

1

with reference to HAdV-3p strain GB full genome sequence (Genbank accession #AY599834)

2

see reference (Kitagawa, 1991)
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(20 mM Tris-HCl [pH 8], 137 mM NaCl, 1 mM EGTA, 1% TritonX-100, 10% glycerol,
1.5 mM MgCl2, 1 mM sodium vanadate, 50 mM NaF, complete mini protease inhibitor
cocktail (Roche, Basel, Switzerland)), and the debris was removed by centrifugation for
15 min at 16,000 x G. The supernatant (membrane fraction) was collected. Samples
were analyzed for total protein content by a standard Bradford assay (Bradford, 1976).

Protein extraction and glycosidase treatment
At the time of harvest, cells in 100 mm culture dishes were washed twice with
ice-cold PBS and incubated on ice with RIPA buffer (50 mM Tris-HCl [pH 8], 150 mM
NaCl, 1% NP-40, 0.5% sodium deoxycholate) containing protease inhibitor cocktail
(complete Mini, Roche, Basel, Switzerland) for 5 min. Cell lysates were collected and
clarified by centrifugation at 16,000 x G for 15 min to remove cellular debris. The
supernatants were analyzed for total protein content by a standard Bradford assay
(Bradford, 1976).
Aliquots of transfected cell lysates containing 40 μg of total protein or the
digestion control fetuin were digested using reagents included in the Enzymatic Protein
Deglycosylation Kit (Sigma, St. Louis, MO). All digestions were carried out at 37˚C.
For digestion with PNGase, 1 µL of enzyme was added to the reaction mixture as
indicated in the manufacturer’s instructions and incubated for 3 h. For digestion with Oglycosidase and neuraminidase, 1 µL of neuraminidase was first added to the reaction
mixture and incubated for 3 h, and then O-glycosidase was added and incubated for an
additional 3 h. For digestion with all three glycosidases, the sequence of enzyme addition
was PNGase, neuraminidase, and O-glycosidase. After addition of each enzyme, reaction
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mixtures were incubated for 3 h. Samples (10.4 µL) were separated under reducing
conditions in MOPS running buffer using NuPAGE 12% polyacrylamide Bis-Tris gels
(Invitrogen,

Carlsbad,

CA)

following

the

manufacturer’s

instructions

and

electrophoretically transferred to PVDF membranes as described below (Invitrogen,
Carlsbad, CA).

Immunoprecipitations
Rabbit anti-HA conjugated beads (15 µL) (Abcam, Cambridge, MA) were added
to an aliquot of cell lysate containing 1 mg of total protein, further diluted to 500 µL with
RIPA buffer containing protease inhibitor cocktail (Roche, Basel, Switzerland), and
incubated overnight at 4˚C with rotation. Beads were collected at 500 X G for 30 sec and
washed 3 times for 5 min in cold RIPA buffer with protease inhibitor cocktail (Roche,
Basel, Switzerland). Bound protein was then eluted in 60 µL of sample buffer with
reducing agent by heating at 70˚C for 10 min. Samples (15 µL) were separated under
reducing conditions in MES running buffer using NuPAGE 12% polyacrylamide Bis-Tris
gels

(Invitrogen,

Carlsbad,

CA)

following

manufacturer’s

instructions

and

electrophoretically transferred onto PVDF membranes for analysis as described below.

Western blot
Protein samples were transferred from polyacrylamide gels to PVDF membranes
(Bio-Rad, Hercules, CA) for 35 min at 100 volts in transfer buffer containing 50 mM
Tris-base, 380 mM glycine, 0.1% SDS, and 20% methanol. The membrane was blocked
with 5% (w/v) non-fat dry milk in 0.1% (v/v) Tween-20 TBS (blocking buffer) for 1 h at
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room temperature. The primary antibody was diluted 1:1000 in blocking buffer and
incubated with the membrane overnight at 4˚C with rocking. After washing in 0.1% (v/v)
Tween-20 TBS (TBS-T), the membrane was incubated with peroxidase-conjugated
AffiniPure goat anti-mouse IgG (H+L) (Jackson ImmunoResearch) diluted 1:100,000 in
blocking buffer for 1 h at room temperature. After washing, the membrane was treated
with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer Life Sciences,
Waltham, MA) according to manufacturer’s instructions and exposed to blue X-ray film.
For Western blot analysis of membrane fractionation experiments, the PVDF membrane
was treated with SuperSignal West Femto Maximum Sensitivity Substrate (Thermo
Scientific, Rockford, IL).

Immunofluorescence microscopy
Transfected cells grown on coverslips were washed three times in PBS and fixed
in 4% (w/v) paraformaldehyde in PBS for 15 min at room temperature at 24 h postinduction with tetracycline. Fixation was quenched by washing with 100 mM glycine
PBS 3 times for 5 min. Cells were permeabilized by treatment with 0.2% (v/v) Triton X100 in PBS for 2 min at room temperature. Coverslips were washed 3 times in PBS and
blocked for 1 h with 10% (v/v) goat or donkey serum in 0.1% (v/v) Tween-20 PBS (PBST) at room temperature with rocking.

Between blocking, primary, and secondary

incubations, coverslips were washed three times in PBS-T. After secondary antibody
incubation in the dark, coverslips were washed three times in PBS-T and three times in
PBS. Coverslips were briefly submerged in ddH2O to remove excess salt and mounted in
Slowfade Gold with DAPI (Molecular Probes, Carlsbad, CA) on glass slides.
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For

staining with wheat germ agglutinin Alexa Fluor 647 conjugate (WGA-647) (Molecular
Probes, Carlsbad, CA), transfected cells on coverslips were rinsed 3 times in PBS and
incubated for 10 min at 37˚C with 200 µL of 5 µg/mL of WGA-647 in PBS. Cells were
then fixed, quenched, and mounted as indicated above.
Images were generated with a Zeiss epifluorescence Axioskop with Hamamatsu
Digital camera controlled with SlideBook Image Analysis software version 4.0
(Intelligent Imaging Innovations, Denver, CO). Images were deconvolved using the
nearest neighbor algorithm contained within the SlideBook software and figures were
prepared using Adobe Photoshop CS3, version 10.0.1 (Adobe Systems Inc., San Jose,
CA).

Propidium iodide permeability of E. coli
ECOS-21 bacteria transformed with pGEX-5x-1 plasmid constructs were grown
overnight at 37ºC with moderate shaking in 2xYT broth (Amresco, Solon, Ohio)
supplemented with 100 μg/ml ampicillin and 1% (w/v) glucose (2xYTAG). Cultures
were diluted 1:20 into 2xYTAG and incubated at 37ºC with moderate shaking. When the
OD600 reading reached 0.5, cultures were induced with 1.0 mM IPTG. Samples for
Western blot analysis and propidium iodide staining were taken at 0 and 3 h post
induction.
Samples of induced cultures (80 μL) were pelleted at max speed for 1 minute and
washed once in PBS. Propidium iodide in PBS (500 μL of 10 μg/ml) was added to
bacteria and incubated at 37ºC in the dark for 10 min. Cells were subsequently washed 2
times in PBS and suspended in an appropriate volume of PBS for analysis on a
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FACScalibur flow cytometer (Becton Dickenson Biosciences, San Jose, CA).

The

bacterial cell population was gated and signals from 10,000 events were collected.
Samples of induced cultures (750 μL) were pelleted at max speed for 1 min,
supernatant was aspirated, and pellets were frozen at -20ºC. Pellets were resuspended in
200 μL B-PER reagent (Pierce, Rockford, IL) and vortexed for 1 min to lyse cells.
Lysates (10 μL) were boiled for 5 min with 20 μL Laemmli buffer, loaded in 10% TrisGlycine SDS-PAGE gels and transferred to PVDF membranes as indicated above.

Permeability of HeLa T-RExTM cells to trypan blue
HeLa T-RExTM cells were plated at approximately 50% confluency in 6-well
culture plates. One day post-plating, medium was aspirated and replaced with either
HeLa T-RExTM Induction Medium (induced) or HeLa T-RExTM Selection Medium
(uninduced). At 48 h post induction, medium was collected and cells were trypsinized.
Medium and cells were pooled and stained with an equal volume of 0.4% Trypan Blue
solution (Sigma, St. Louis, MO). Cells (~200) were counted with a light microscope and
a hemocytometer. Percent cell viability was determined by dividing the number of
unstained cells by the total number of cells counted and multiplying by 100.

Construction of HAdV-3p mutant viruses
A schematic of the strategy to generate HAdV-3p mutant viruses is presented in
Figure 5. The highly efficient bacteriophage λ Red recombination system (Poteete, 2001)
was used to generate HAdV-3p clones encoding a C-terminus HA epitope-tagged version
of ORF E3-10.9K (HAdV-3p-9K-HA), ORF E3-10.9K from HAdV-7h strain Argentina
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87-922 (HAdV-3p-NULL), ORF E3-10.9K with all in-frame ATG codons mutated to
TAG stop codons (HAdV-3p-KO), and a recombination control (HAdV-3p-9K).
The bacmid pKSB2Ad3wt, harboring the full-length genome of HAdV-3
prototype strain GB, was a kind gift of Dr. Silvio Hemmi (Sirena et al., 2005). Dr.
Samuel Campos (University of Arizona) generated a shuttle plasmid, pE3-9K, to
facilitate modification of ORF E3-10.9K within pKSB2Ad3wt. The pE3-9K shuttle (Fig.
5A) was constructed by PCR cloning a C-terminal fragment of ORF E3-20.5K into the
HindIII/BamHI sites of plasmid pFZF (Campos and Barry, 2004), just upstream of the
zeocin resistance gene flanked by Flp recognition target (FRT) sites. A SalI site was
included just upstream of the BamHI site in the primer design. Next, the region just
downstream of ORF E3-10.9K, containing ORFs E3-10.2K, E3-15.2K, and a fragment of
ORF E3-15.3K was PCR-amplified from pKSB2Ad3wt and cloned into pFZF with NheI
and NotI. The pE3-9K shuttle was designed in such a way that any gene of interest could
be cloned into the SalI/BamHI sites to replace ORF E3-10.9K of pKSB2Ad3wt upon
recombination.
ORF E3-10.9K was either replaced with a C-terminus HA-tagged version of ORF
E3-10.9K or the ORF E3-10.9K ortholog encoded by HAdV-7h strain Argentina 87-922,
designated E3-NULL, by cloning into pE3-9K shuttle using the SalI/BamHI sites.
Alternatively, the pE3-9K shuttle plasmid was subjected to site-directed mutagenesis to
mutate all ORF E3-10.9K’s in-frame ATG codons to TAG stop codons. The altered pE39K shuttle plasmids were then linearized with HindIII and PvuI. The purified linear
fragment was then transformed by electroporation into E. coli strain BW25113, harboring
the pKSB2Ad3wt bacmid and the temperature sensitive replicon pKD46, which
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expressed the λ Red genes under the arabinose-inducible pBAD promoter (Datsenko and
Wanner, 2000). Electroporation was performed in a 0.2 cm gap cuvette with a
micropulser (Biorad) set to 2500 V. Electroporated cells were resuspended in SOC +
0.5% L-arabinose and incubated overnight at room temperature. Induction of the λ Red
genes resulted in recombination between the linear pE3-9K fragment and the HAdV-3p

Figure 5. ORF E3-9K shuttle plasmid and recombination strategy. (A) Map of the
pE3-9K shuttle plasmid with unique restriction sites. Sequences cloned into the SalI and
BamHI sites replace ORF E3-9K of the HAdV-3p genomic bacmid upon recombination.
(B) Transformation of the linearized shuttle plasmid containing the desired ORF E310.9K mutations into λ Red recombination E. coli strain BW25113, containing the
HAdV-3p genomic bacmid results in recombination across homologous regions. (C)
Recombinant bacmids are selected by growth under chloramphenicol and zeocin
selection. (D) Transformation of this recombinant into E. coli strain SW105 causes
collapse across the FRT sites and deletion of the zeocin resistance cassette to generate
final pAd3-9K bacmids.
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bacmid. Recombinant pAd3-9K- FZF clones were selected by plating at 37°C on 15
μg/mL chloramphenicol and 25 μg/mL zeocin (Fig. 5B, C). Recombinant pAd3-9K-FZF
bacmids were then purified and electroporated into E. coli strain SW105 (Warming et al.,
2005), which expressed Flp recombinase under arabinose control. Incubation overnight at
room temperature in SOC + 0.5% L-arabinose induced Flp recombinase expression,
which collapsed the FZF cassette into a single 34 bp FRT site. Transformed cells were
plated at 30°C on chloramphenicol (15 μg/mL). Several colonies were picked and
screened for sensitivity to zeocin, as proper Flp recombination resulted in loss of zeocin
resistance (Fig. 5D). Final pAd3-9K clones were screened by restriction digestion and
sequenced to confirm the presence of the desired mutations to ORF E3-10.9K. The
recombination described above ultimately resulted in a new SalI site between ORF E320.5K and ORF E3-9K as well as a BamHI site, the 34 bp FRT scar site, and an NheI site
between ORF E3-10.9K and ORF E3-10.2K in the E3 transcription unit (Fig. 5D). A
recombinant pAd3-9Kwt containing the unmodified wild type ORF E3-9K was also
constructed to control for the introduction of these additional elements into the HAdV-3p
genome.
DNA from pAd3-9K mutant bacmids and pKSB3Ad3wt were digested with MluI
to release the viral genomic DNA. This digest was then transfected into A549 cells using
Effectene Reagent (Qiagen, Valencia, CA). Two µg digested bacmid DNA were used
per transfection. Transfected cells were incubated for 14 days. For virus recovery, cells
were subjected to 3 freeze-thaw cycles at -80˚C and 25˚C, and clarified by centrifugation.
The resultant virus was propagated by passage in A549 cells, and presence of virus was
confirmed by observation of characteristic AdV cytopathic effect (CPE). Titered stocks
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of HAdV-3p mutant viruses and HAdV-3p-WT virus were generated as indicated above.
The identities of the mutant viruses were confirmed by sequencing of the E3 transcription
unit and restriction enzyme analysis with BamHI and SalI (data not shown).

Ara-C inhibition of viral DNA replication
A549 cells were infected at a MOI of 10 PFU/cell and incubated in Ara-C
supplemented A549 Infection Medium as indicated above. At 8 at 48 h pi, cell lysates
were harvested in RIPA buffer and protein content was determined by a standard
Bradford assay (Bradford, 1976).

Dissemination assay
A549 cells were plated on 24-well culture plates and infected at a MOI of 1, 0.1,
or 0.01 PFU/cell for each virus. Infected cells were incubated for 5 days, medium was
aspirated, and cells were fixed in 1% formaldehyde and stained with Accustain crystal
violet solution (Sigma-Aldrich).

Plaque size assay
A549 cells were plated on 6-well culture plates, infected with approximately 20
PFU per well, and replenished with a semi-solid agarose/medium overlay. Plates were
incubated for 13 days and then fixed in 1% formaldehyde and stained with Accustain
crystal violet solution (Sigma-Aldrich).
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Virus egress assay
A549 cells were infected at a MOI of 10 PFU/cell. After 1 h adsorption at 37˚C,
cells were washed 3 times in PBS to remove excess extracellular virus. At 6, 12, 24, 36,
48, 72, 96, and 120 h pi, extracellular and total virus was harvested. For total virus
samples, infected cells and supernatant were collected and freeze-thawed 3 times at -80˚C
and room temperature. Samples were centrifuged at 300 x G for 5 min to remove cellular
debris, and supernatant was collected. For extracellular virus samples, supernatant from
infected cells was collected and transferred to a 5 mL round-bottom culture tube. Cells
and debris were removed by centrifuging at 300 x G for 5 min, and supernatant was
collected. Infectious virus in samples was determined by plaque assay on A549 cells.

Infected cell viability assay
A549 cells were infected at a MOI of 10 PFU/cell. At 24, 48, 72, 96, and 120 h
pi, medium was collected from cells and transferred to a tube. Cells were trypsinized and
pooled with medium. Pooled samples were mixed with an equal volume of 0.4% Trypan
Blue solution (Sigma, St. Louis, MO) and ~200 cells were counted using a light
microscope and a hemocytometer. The percent of viable cells was calculated by dividing
the number of unstained cells by the total number of cells counted and multiplying by
100.
Live cell microscopy
A reflected fluorescence microscope (CKX41, Olympus) with an attached Infinity
2-3C digital camera (Lumenera) was used to capture images of CPE and live cell
fluorescence.
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Chapter 4: Results--Biochemical characterization of ORF E3-10.9K

ORF E3-10.9K previously showed a marked genetic polymorphism among
subspecies B1 HAdV lab strains and field isolates (Kajon et al., 2005). No biochemical
or functional studies of ORF E3-10.9K-encoded protein products have been carried out to
date. To elucidate the functional role(s) of ORF E3-10.9K during the HAdV life-cycle,
we carried out an initial characterization of several predicted ORF E3-10.9K-encoded
protein orthologs using bioinformatics sequence-based protein prediction tools, RT-PCR
detection of transcripts during infection with subspecies B1 HAdVs, and fluorescence
microscopy to investigate the subcellular localization of ectopically expressed proteins.

Predicted structural features of ORF E3-10.9K-encoded protein orthologs
Kyte-Doolittle hydrophobicity plots were generated and analyzed for several
predicted ORF E3-10.9K-encoded protein orthologs encoded by subspecies B1 HAdV
field isolates.

A 19-amino-acid-long hydrophobic region predicted to be a

transmembrane domain was identified in the backbones of the 7.7 kDa, 9 kDa, and 10.9
kDa orthologs (Fig. 6). A smaller protein ortholog, 4.8 kDa, did not contain this
hydrophobic domain (Fig. 6). Protein topology predictions showed the C-terminus in a
cytoplasmic orientation (Ccyt) for 10.9 kDa and 9 kDa protein orthologs and the Nterminus in the cytoplasmic orientation (NCyt) for the 7.7 kDa protein ortholog.
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Figure 6. Kyte-Doolittle hydrophobicity plots of selected ORF E3-10.9K-encoded
protein orthologs. Amino acid sequences of 4.8 kDa, 7.7 kDa, 9 kDa, and 10.9 kDa
ORF E3-10.9K protein orthologs were analyzed using Protean and web-based TopPred
software programs (see Chapter 3: Materials and Methods). Predicted protein topology is
indicated by Cyt (cytoplasm) or Ext (extracellular/lumen). Positive values (above the
center line) denote hydrophobic domains, negative values (below the center line) denote
hydrophilic domains.

Species C HAdV E3-11.6K/ADP is post-translationally modified by N- and Olinked glycans (Scaria et al., 1992; Tollefson et al., 2003). In order to investigate if the
ORF E3-10.9K protein orthologs were likely to be N- or O-glycosylated as well, we used
a web-based glycosylation prediction tool to identify potential N- and O-linked
glycosylation sites for the 4.8 kDa, 7.7 kDa, 9 kDa, and 10.9 kDa orthologs. These data
suggested that the 4.8 kDa, 7.7 kDa, and 10.9 kDa orthologs contained two potential Nlinked glycosylation sites, whereas the 9 kDa ortholog contained one potential N-linked
glycosylation site (Fig. 7). No O-glycosylation sites were predicted for the any of the
orthologs analyzed.
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Another interesting predicted feature of ORF E3-10.9K-encoded protein orthologs
was the presence of a region rich in basic amino acids (polybasic region). This polybasic
region was present in the 9 kDa and 10.9 kDa orthologs, but was absent in the 7.7 kDa
and 4.8 kDa orthologs (Fig. 7). Additionally, the 7.7 kDa, 9 kDa, and 10.9 kDa orthologs
had aromatic amino acids in or near their hydrophobic domains (Fig. 7). Taken together,
the presence of a polybasic region, aromatic residues in the hydrophobic domain of the
ORF E3-10.9K-encoded proteins, and their small size suggest these proteins are
membrane-active proteins similar to viroporins.

Figure 7. Predicted amino acid sequences of selected ORF E3-10.9K-encoded
protein orthologs.
Hydrophobic domain, polybasic region, and predicted Nglycosylation sites are indicated. Aromatic amino acids are indicated in bold. Adapted
from Kajon et al., 2005.

Detection of ORF E3-10.9K-encoded protein in infected cells
Two independent attempts to raise anti-E3-10.9K rabbit antisera by immunizing
with KLH-conjugated 15-mers representing the regions with the highest antigenic index
for the detection of ORF E3-10.9K-encoded protein orthologs were unsuccessful. Rabbit
antisera had high levels of cross-reactivity with viral and host proteins, and did not
recognize an EGFP-tagged 10.9 kDa fusion protein by Western blot. As an alternative
strategy, we generated a HAdV-3p mutant virus encoding the 9 kDa protein ortholog as a
C-terminus HA-tagged polypeptide (HAdV-3p-9K-HA). A549 cells were infected at a
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MOI of 10 PFU/cell and harvested at 48 h pi. Membrane and cytosolic fractions were
isolated and detection of the 9 kDa-HA protein was carried out by immunoblot using an
anti-HA antibody (Fig. 8). These data showed that the 9 kDa-HA protein was associated
with the membrane fraction, as predicted by Kyte-Doolittle hydrophobicity plots (Fig. 6).

Figure 8. Western blot analysis of HA-tagged 9 kDa protein in cytosolic and
membrane fractions of HAdV-3p-9K-HA infected A549 cells. A549 cells were
infected at a MOI of 10 PFU/cell with HAdV-3p-9K-HA mutant virus and harvested at
48 h pi for membrane fractionation. Samples (10 μg) were separated under reducing
conditions using NuPAGE 12% polyacrylamide Bis-Tris gels in MES running buffer and
transferred to a PVDF membrane. The membrane was probed with a monoclonal mouse
anti-HA antibody (primary) and a polyclonal HRP-conjugated goat anti-mouse antibody
(secondary). C: cytosolic fraction, M: membrane fraction.
Expression from the adenovirus major late promoter
Species C HAdV E3-11.6K/ADP is expressed at late times pi from the AdV MLP
(Tollefson et al., 1992). Because ORF E3-10.9K is located in the E3 transcription unit in
an analogous region to ORF E3-11.6K/ADP, we hypothesized that ORF E3-10.9K would
also be expressed from the MLP. To test this hypothesis, we infected A549 cells with
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subspecies B1 HAdVs representing genomic variants encoding different protein
orthologs. Total RNA was isolated at 8 and 24 h pi, and RT-PCR was carried out to
detect ORF E3-10.9K transcripts (Fig. 9). For all viruses tested, we detected expression

Figure 9. Expression of ORF E3-10.9K from the adenovirus major late promoter.
A549 cells were infected at a MOI of 5 PFU/cell with subspecies B1 HAdVs encoding
different predicted ORF E3-10.9K orthologs (A) or HAdV-3p-9K-HA mutant virus (B).
RNA was harvested at 8 and 24 h pi and analyzed by RT-PCR using primers listed in
Table 5. Primer pairs were: E3-10.9K forward and E3-10.9K reverse (E3-10.9K
internal), TPL3 forward and E3-10.9K reverse Tm60 (TPL/E3-10.9K), TPL3 forward and
Hexon reverse (TPL/Hexon), and RIG/s15 forward and RIG/s15 reverse (RIG). RIG was
a positive control for RT and TPL/Hexon was a positive control for viral late gene
expression. Mock-infected cells (M) were used as a negative control.

of ORF E3-10.9K at both 8 and 24 h pi using primers internal to ORF E3-10.9K (Fig.
9A). To detect transcripts generated from the MLP, we used an upstream primer specific
for leader 3 of the TPL and a downstream primer internal to ORF E3-10.9K (Fig. 2). The
TPL sequence is spliced onto all transcripts expressed from the MLP (Berget et al.,
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1977), making it a useful feature for the detection of MLP transcripts. Using this
strategy, strong expression of ORF E3-10.9K from the MLP was detected at 24 h pi,
similar to the control PCR detecting the expression of a hexon gene (a known late
transcript) from the MLP (Fig. 9A). The same experiment was carried out with the
HAdV-3p-9K-HA mutant virus to confirm expression from the MLP (Fig. 9B).
To determine the identity of the RT-PCR products, the approximately 800 bp and
300 bp bands were gel-purified and sequenced.

Additionally, a smaller product of

approximately 200 bp present only in the HAdV-3p and HAdV-3p-9K-HA samples was
purified and sequenced. Sequence data showed that the 800 bp bands contained the TPL
sequence immediately preceding ORF E3-20.5K and contained ORF E3-10.9K. The 300
bp bands contained the TPL sequence 6 bp upstream of ORF E3-10.9K (Genbank
accession numbers: GU951413-GU951425). The smaller products present only in the
HAdV-3p and HAdV-3p-9K-HA samples contained the TPL sequence and a non-coding
C-terminus domain of ORF E3-10.9K. These data suggest that ORF E3-10.9K is indeed
expressed from the AdV MLP, similar to the species C HAdV E3-11.6K/ADP.
Having found that ORF E3-10.9K was expressed at late times pi from the AdV
MLP, similar to species C HAdV E3-11.6K/ADP, we next wanted to determine whether
the protein was also expressed at late times pi. We infected A549 cells with the HAdV3p-9K-HA mutant virus, harvested infected cells at 8 and 48 h pi, and detected the 9 kDaHA protein by immunoprecipitation and Western blot. The 9 kDa-HA protein was
detected at 48 h pi, but we were unable to detect the protein at 8 h pi, suggesting that the
protein was primarily expressed at late stages of infection (Fig. 10). To determine
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Figure 10. Expression of HA-tagged 9 kDa protein requires viral DNA replication.
A549 cells were infected at a MOI of 10 PFU/cell and either treated with Ara-C to inhibit
viral DNA replication and arrest cells at the early stage of infection (+) or mock-treated
(-). Cell lysates were collected at 8 and 48 h pi, and 100 μg of total protein were
immunoprecipitated with rabbit anti-HA conjugated agarose beads and analyzed by
Western blot. Samples were separated under reducing conditions on a NuPAGE 12%
polyacrylamide Bis-Tris gel in MES buffer, and transferred to a PVDF membrane. The
membrane was probed with a monoclonal mouse anti-HA antibody (primary) and a
polyclonal HRP-conjugated goat anti-mouse antibody (secondary).

whether the expression of the 9 kDa-HA protein at late times during infection required
viral DNA replication, cells were treated throughout infection with Ara-C to inhibit DNA
synthesis. When infected cells were treated with Ara-C, we were unable to detect the 9
kDa-HA protein at 48 h pi, indicating that the expression of the protein required viral
DNA replication (Fig. 10). These data support our findings that the ORF E3-10.9K is
present on MLP transcripts at late times post infection (Fig. 9), since expression from the
MLP requires viral DNA replication.
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Glycosylation of proteins
Several products of a higher molecular weight than expected were detected at late
times pi in cells infected with HAdV-3p-9K-HA (Fig. 10). These data suggested that the
9 kDa-HA protein was post-translationally modified. Additionally, N-glycosylation sites
were predicted for the 7.7 kDa, 9 kDa, and 10.9 kDa protein orthologs (Fig. 7). To
investigate whether ORF E3-10.9K-encoded protein orthologs were glycosylated, we
generated HeLa T-RExTM cell lines that expressed C-terminal EGFP-tagged ORF E310.9K-encoded orthologs under tetracycline regulation. Protein expression was induced
with tetracycline and cell lysates were collected at 48 h pi. Total protein samples were
incubated with PNGase, neuraminidase, and/or O-glycosidase. Electrophoretic mobility
in the observed molecular weight were analyzed by Western blot (Fig. 11). Initially,
undigested protein showed higher MW bands for the 7.7 kDa-EGFP, 9 kDa-EGFP, and
10.9 kDa-EGFP proteins (Fig. 11A). Upon digestion with PNGase to remove N-linked
glycans, shifts in electrophoretic mobility were observed for 7.7 kDa-EGFP, 9 kDaEGFP, and 10.9 kDa-EGFP (Fig. 11B). Digestion with neuraminidase and O-glycosidase
to remove most O-linked glycans showed slight shifts in electrophoretic mobility for 7.7
kDa-EGFP and 10.9 kDa EGFP, but not 9 kDa-EGFP (Fig. 11B). Digestion with all
three glycosidases to remove all N- and most O-linked glycans revealed further shifts in
electrophoretic mobility for 7.7 kDa-EGFP and 10.9 kDa-EGFP (Fig. 11B). However,
digestion with glycosidases did not return the proteins to their predicted, unmodified size
(Fig. 11B). These data suggested that 7.7 kDa-EGFP and 10.9 kDa-EGFP were N- and
O-glycosylated, but 9 kDa-EGFP was only N-glycosylated. These data also suggested
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that the proteins contained additional post-translational modifications that were not
removed by treatment with PNGase, O-glycosidase, and neuraminidase.

Figure 11. Glycosylation patterns of ORF E3-10.9K protein orthologs. C-terminus
EGFP-tagged 4.8 kDa, 7.7 kDa, 9 kDa, and 10.9 kDa were expressed under tetracycline
regulation in HeLa-TRExTM cells. Total protein was separated under reducing conditions
on 12% polyacrylamide NuPAGE gels in MOPS buffer and transferred to PVDF
membranes. The membranes were probed with a monoclonal mouse anti-EGFP antibody
(primary) and a polyclonal HRP-conjugated goat anti-mouse antibody (secondary). (A)
10 µg of undigested total protein were analyzed. (B) 40 µg of total protein were digested
with PNGase, Neuraminidase, or O-glycosidase to remove N- or O-linked glycans.
Approximately 10 µg of protein from digest was analyzed. A fetuin protein digestion
control was analyzed in parallel by Coomassie staining to confirm complete digestion
with glycosidases (data not shown). *: unmodified EGFP-fusion proteins.

Localization of EGFP-fusions
Having found that the 9 kDa-HA protein was present in the membrane fraction of
infected cells, we next investigated the subcellular localization of ORF E3-10.9Kencoded protein orthologs.

We stained transiently-transfected HeLa T-RExTM cells

expressing C-terminal EGFP-tagged ORF E3-10.9K-encoded protein orthologs with
WGA-647, a plasma membrane marker that specifically binds to sialic acid and N63

acetylglucosaminyl residues (Fig. 12). Co-localization with WGA-647 was observed for
the 9 kDa-EGFP and 10.9 kDa-EGFP proteins but not for the 7.7 kDa-EGFP or 4.8 kDaEGFP proteins (Fig. 12, merge panels). The 7.7 kDa-EGFP protein appeared to localize
primarily to a juxtanuclear compartment, but no co-localization was detected with either
calnexin (endoplasmic reticulum marker), Golgin97 (a trans-Golgi marker), or 58K-Golgi
protein (a Golgi marker) (Fig. 13, 14, 15, 7.7 kDa panels). The 4.8 kDa-EGFP protein
showed diffuse cellular localization similar to that observed for EGFP alone (Fig. 12, 13,
14, 15, 4.8 kDa panels). These data suggest that the C-terminus and hydrophobic domain
of the protein are necessary for localization to the plasma membrane, since the 9 kDa and
10.9 kDa proteins contain the C-terminus and the hydrophobic domain while the 4.8 kDa
and 7.7 kDa proteins do not.
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Figure 12. Cellular co-localization of C-terminal EGFP-tagged ORF E3-10.9Kencoded protein orthologs with plasma membrane marker (WGA-647). HeLaTRExTM cells were transfected with plasmids expressing EGFP-tagged ORF-E3-10.9Kencoded protein orthologs under a tetracycline inducible promoter. Expression was
induced with 1 μg/mL of tetracycline for 24 h. Cells were fixed, stained with WGA-647
(plasma membrane) and DAPI (nucleus), and analyzed by immunofluorescence
microscopy. Merge images show pseudo-colored EGFP (green), WGA-647 (red), DAPI
(blue) and overlapping EGFP and WGA-647 as yellow.
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Figure 13. Cellular co-localization of C-terminal EGFP-tagged ORF E3-10.9Kencoded protein orthologs with endoplasmic reticulum marker (Calnexin). HeLaTRExTM cells were transfected with plasmids expressing EGFP-tagged ORF-E3-10.9Kencoded protein orthologs under a tetracycline inducible promoter. Expression was
induced with 1 μg/mL of tetracycline for 24 h. Cells were fixed, stained with a
monoclonal mouse anti-calnexin antibody (primary), a polyclonal Cy5-conjugated
donkey anti-mouse antibody (secondary), and DAPI (nucleus) and analyzed by
immunofluorescence microscopy. Merge images show pseudo-colored EGFP (green),
calnexin (red), DAPI (blue) and overlapping EGFP and calnexin as yellow.
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Figure 14. Cellular co-localization of C-terminal EGFP-tagged ORF E3-10.9Kencoded protein orthologs with trans-Golgi marker (Golgin97). HeLa-TRExTM cells
were transfected with plasmids expressing EGFP-tagged ORF-E3-10.9K-encoded protein
orthologs under a tetracycline inducible promoter. Expression was induced with 1 μg/mL
of tetracycline for 24 h. Cells were fixed, stained with a monoclonal mouse anti-Golgin97
antibody (primary), a polyclonal Cy5-conjugated donkey anti-mouse antibody
(secondary), and DAPI (nucleus) and analyzed by immunofluorescence microscopy.
Merge images show pseudo-colored EGFP (green), Golgin97 (red), DAPI (blue) and
overlapping EGFP and Golgin97 as yellow.
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Figure 15. Cellular co-localization of C-terminal EGFP-tagged ORF E3-10.9Kencoded protein orthologs with Golgi marker (58K-Golgi). HeLa-TRExTM cells were
transfected with plasmids expressing EGFP-tagged ORF-E3-10.9K-encoded protein
orthologs under a tetracycline inducible promoter. Expression was induced with 1 μg/mL
of tetracycline for 24 h. Cells were fixed, stained with a monoclonal mouse anti-58KGolgi antibody (primary), a polyclonal Cy5-conjugated donkey anti-mouse antibody
(secondary), and DAPI (nucleus) and analyzed by immunofluorescence microscopy.
Merge images show pseudo-colored EGFP (green), 58K-Golgi (red), DAPI (blue) and
overlapping EGFP and 58K-Golgi as yellow.
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Chapter 5: Results--Membrane permeabilizing activity of ORF E3-10.9K-encoded
protein orthologs

Results from our initial characterization of ORF E3-10.9K-encoded proteins
suggest that the protein orthologs with a hydrophobic domain are likely membrane-active
proteins because of their high hydrophobicity, the presence of polybasic regions and
aromatic residues in or near the hydrophobic domain, and their localization to cellular
membranes. We hypothesized that ORF E3-10.9K-encoded protein orthologs with a
hydrophobic domain were membrane-active proteins.

Permeabilization of membranes in E. coli expressing N-term GST E3-10.9K fusions
We first investigated the ability of ORF E3-10.9K-encoded protein orthologs to
permeabilize membranes using an established E. coli expression system.

E. coli were

transformed with plasmids that expressed N-terminus GST-tagged ORF E3-10.9Kencoded orthologs under an inducible lac promoter. Cells were collected and stained
with propidium iodide at 0 and 3 h post induction of fusion protein expression, and
analyzed by flow cytometry. Neither GST alone nor GST-4.8 kDa showed any shift in
fluorescence intensity after 3 h of protein expression (Fig. 16A). However, GST-7.7
kDa, GST-9 kDa, and GST-10.9 kDa showed a marked shift in fluorescence intensity
after induction of protein expression, suggesting that the presence of a hydrophobic
domain is necessary for permeabilizing E. coli to propidium iodide (Fig. 16A).

69

Expression of GST-fusion proteins was confirmed by Western blot with anti-GST
antibody (Fig. 16B).

Figure 16. Permeability of E. coli expressing GST fusions of ORF E3-10.9Kencoded protein orthologs to propidium iodide. (A) E. coli transformed with pGEX
bacterial expression constructs expressing ORF E3-10.9K-encoded protein orthologs as
N-terminal GST fusions were cultured and fusion-protein expression was induced with
1.0 mM IPTG. Samples (80ul) were removed from the cultures at 0 and 3 h post
induction, washed, incubated with propidium iodide in PBS (10 μg/mL), washed, and
analyzed by flow cytometry. E. coli that were unstained or expressing GST only were
used as negative controls. (B) Samples of uninduced (-) and induced (+) cultures were
taken at the same time as samples for propidium iodide staining, separated on a 10% TrisGlycine SDS-PAGE gel, and transferred to a PVDF membrane. The membrane was
probed with a polyclonal goat anti-GST antibody (primary) and a polyclonal HRPconjugated rabbit anti-goat antibody (secondary) to confirm expression of GST-fusion
proteins.
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Permeabilization of membranes in mammalian cells expressing C-term EGFP E3-10.9K
fusions
Having found that ORF E3-10.9K-encoded protein orthologs with a hydrophobic
domain were capable of permeabilizing membranes in an E. coli expression system, we
next wanted to investigate their ability to permeabilize mammalian cell membranes. For
this experiment, stably transfected HeLa T-RExTM cells expressing C-terminal EGFPtagged ORF E3-10.9K-encoded orthologs under a tetracycline inducible promoter were
used. Fusion protein expression was induced at 24 h post plating, and permeability of the
cells to trypan blue was assessed by light microscopy.

Upon induction of protein

expression, no change in permeability of HeLa T-RExTM cells to trypan blue was
observed, suggesting that ORF E3-10.9K-encoded protein orthologs were not able to
permeabilize mammalian membranes or compromise cell viability (Fig. 17A).
Expression of EGFP-fusion proteins in transfected cells after tetracycline induction was
confirmed by fluorescence microscopy (Fig. 17B).
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Figure 17. Permeability of HeLa T-RExTM cells to trypan blue upon expression of
EGFP-tagged ORF E3-10.9K-encoded protein orthologs. HeLa T-RExTM cells stably
transfected with pCDNA 4/TO expression plasmids were treated with 1 μg/mL
tetracycline (+ Tet) or mock treated (- Tet). (A) At 48 h post treatment, medium was
removed and cells were collected by trypsinization. Medium and cells were pooled and
stained with an equal volument of 0.4% trypan blue solution. Cells (~200) were counted
with a light microscope and a hemocytometer, and the percentage of unstained cells was
calculated. Error bars indicate SEM for three independent experiments. (B) Prior to
trypan blue staining, expression of EGFP-fusion proteins in tetracycline treated (+ Tet) or
untreated (- Tet) live cells was examined by bright field (BF) and fluorescence (EGFP)
microscopy. Images are representative of three independent experiments.

72

Chapter 6: Results--Characterization of HAdV-3p ORF E3-10.9K mutant viruses

The data from our experiments with the HAdV-3p mutant virus expressing a Cterminus HA-tagged 9 kDa protein show that this protein is expressed primarily at late
stages of infection (Fig. 10). Additionally, ORF E3-10.9K is located in an analogous
region of the E3 transcription unit as species C HAdV E3-11.6K/ADP, which is involved
in the efficient release of virus progeny from the host cell at the end of infection
(Tollefson et al., 1996b) (Fig. 3). Because of this, we hypothesized that ORF E3-10.9K
play a role in the efficient release of progeny virions from infected cells. To test this
hypothesis we generated HAdV-3p mutant viruses with mutated ATG codons in the ORF
E3-10.9K and investigated their growth characteristics in A549 cells.

Construction of HAdV-3p ORF E3-10.9K mutant viruses
HAdV-3p encodes a 9 kDa protein in ORF E3-10.9K (Fig. 7).

Using

recombination-based engineering of the HAdV-3p genome (Fig. 5), we generated two
control viruses (HAdV-3p-WT and HAdV-3p-9K) and two viruses unable to express a
protein from the ORF E3-10.9K (HAdV-3p-KO and HAdV-3p-NULL). Figure 18 is a
schematic showing the HAdV-3p mutant viruses generated for these experiments.
HAdV-3p-WT was generated from the pKBS2Ad3wt bacmid and had no alterations to
the E3 transcription unit. HAdV-3p-9K was a recombination control containing SalI and
BamHI restriction sites flanking the ORF E3-10.9K and an FRT scar site. HAdV-3p-KO
had an ORF E3-10.9K with all in-frame ATG codons mutated to TAG stop codons.
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HAdV-3p-NULL contained the non-coding version of ORF E3-10.9K encoded in the
genome of HAdV-7h (encoding a null mutation) in place of ORF E3-10.9K encoding the
9 kDa protein (Fig. 18).

Figure 18. Schematic of HAdV-3p ORF E3-10.9K mutant viruses. Mutant viruses
were generated by recombination with pE3-9K shuttle plasmid, digestion of bacmid with
MluI to release the mutated HAdV-3p genome, transfection into A549 cells, and
propagation of resultant mutant virus (see Materials and Methods). Recombinants
contain SalI and BamHI restriction enzyme sites and an FRT scar site as a result of
recombination. HAdV-3p-WT control virus was generated by digestion of pKSB2Ad3wt
with MluI without prior recombination or mutation. HAdV-3p-9K recombination control
virus was generated by recombination of pKSB2Ad3wt with unaltered pE3-9K shuttle
plasmid in E. coli and digestion with MluI. HAdV-3p-KO mutant virus was generated by
recombination of pKSB2Ad3wt with a pE3-9K shuttle plasmid that contained TAG stop
codons in place of all ORF E3-10.9K in-frame ATG codons. HAdV-3p-NULL was
generated by recombination of pKSB2Ad3wt with a pE3-9K shuttle plasmid that had the
HAdV-7h-encoded null version of ORF E3-10.9K (see Fig. 7) in place of the 9 kDa
version of ORF E3-10.9K.
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Cytopathic effect of HAdV-3p mutant viruses on A549 cell monolayers
A549 cells were infected at a MOI of 1 PFU/cell and analyzed by light
microscopy at 4 days pi. Typical AdV CPE was observed for HAdV-3p-WT (control)
and HAdV-3p-9K (recombination control).

No difference in the progression or

appearance of CPE was observed for the HAdV-3p-KO or HAdV-3p-NULL compared to
controls (Fig. 19).

Figure 19. Cytopathic effect of HAdV-3p ORF E3-10.9K mutant viruses on A549
cells. A549 cells were infected with HAdV-3p control (HAdV-3p-WT, HAdV-3p-9K)
viruses or HAdV-3p ORF E3-10.9K mutant viruses (HAdV-3p-KO, HAdV-3p-NULL) at
a MOI of 1 PFU/cell and analyzed by light microscopy 4 days pi. Classical adenovirus
CPE was characterized by rounding and detaching of cells from culture plate surface and
“webbing” or “lacy” appearance of cells was observed.

Dissemination of HAdV-3p mutant viruses in A549 cell monolayers
We investigated the ability of HAdV-3p mutant viruses to disseminate in A549
cell monolayers. A549 cells were infected with ten-fold dilutions of HAdV-3p mutant
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viruses, replenished with infection medium, and harvested and stained at 5 days pi to
visualize the dissemination of virus. No difference was observed among the control
HAdV-3p-WT, the recombination control HAdV-3p-9K, HAdV-3p-KO, or HAdV-3pNULL (Fig. 20).

Figure 20. Dissemination of HAdV-3p ORF E3-10.9K mutant viruses in A549 cell
monolayers. A549 cells were infected at a MOI of 1, 0.1, or 0.01 PFU/cell, replenished
with liquid medium, fixed at 5 days pi, and stained with crystal violet to visualize virusinduced cells monolayer destruction. This image is representative of three independent
experiments.

HAdV-3p mutant virus plaque formation in A549 cell monolayers
To investigate the ability of HAdV-3p mutant viruses to form plaques in A549
cell monolayers, cells were infected with ~20 PFU under a semi-solid agarose/medium
76

overlay and fixed and stained at 13 days pi to visualize plaques. No difference in the
sizes of plaques was observed between control and mutant HAdV-3p viruses (Fig. 21).

Figure 21. Plaque sizes of HAdV-3p ORF E3-10.9K mutant viruses in A549 cell
monolayers. A549 cells in 6-well plates were infected with ~20 PFU/well and overlayed
with a semi-solid agarose/medium overlay. At 13 days pi, cells were fixed and stained
with crystal violet to visualize plaques. Image is representative of three independent
experiments.

HAdV-3p mutant virus egress from infected cells
To test our hypothesis that ORF E3-10.9K-encoded protein orthologs play a role
in the efficient release of virus progeny from infected cells, we carried out virus release
assays in A549 cells. Cells were infected at a MOI of 10 PFU/cell and extracellular
(supernatant) or total (cells and supernatant) infectious virus yields were determined by
plaque assay. In two independent experiments, no difference was observed among the
control and mutant viruses in either total or extracellular virus yields (Fig. 22).
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Figure 22. HAdV-3p ORF E3-10.9K mutant virus egress from A549 cells. A549
cells were infected with HAdV-3p ORF E3-10.9K mutant viruses at a MOI of 10
PFU/cell, replenished with liquid medium, and total (A, C) or extracellular (B, D)
infectious virus yields were determined by plaque assay at the indicated times pi. Two
independent experiments (A,B and C,D) are shown.
Viability of host cells infected with HAdV-3p mutant viruses
To investigate the role of ORF E3-10.9K on the ability of HAdV-3p to kill
infected cells, we carried out a trypan blue exclusion assay on A549 cells infected with
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HAdV-3p mutant viruses. No difference was observed for the HAdV-3p-NULL or
HAdV-3p-KO compared to control HAdV-3p-WT or recombination control HAdV-3p9K (Fig. 23).

Figure 23. HAdV-3p ORF E3-10.9K mutant virus infected A549 cell viability. A549
cells were infected with HAdV-3p ORF E3-10.9K mutant viruses at a MOI of 10
PFU/cell. Medium and trypsinized cells were pooled at indicated times pi, stained with
an equal volume of 0.4% trypan blue solution, and ~200 cells were counted using a light
microscope and hemocytometer. The percentage of viable cells was determined by
dividing the number of unstained cells by the total number of cells counted. Error bars
indicate standard error of the mean for three independent experiments.
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Chapter 7: Discussion

Based on the observation that ORF E3-10.9K is encoded in an analogous region
of the E3 transcription unit to that of species C HAdV E3-11.6K/ADP and that its
predicted protein products display viroporin-like features, we initially hypothesized that
ORF E3-10.9K-encoded proteins were implicated in the efficient release of virus progeny
at late stages of infection through a mechanism of action that involved the
permeabilization or destabilization of host cellular membranes.

The results of our

experiments using HAdV-3p mutant viruses unable to express ORF E3-10.9K suggest
that this hypothesis is incorrect. However, interesting data were obtained to support the
likelihood that ORF E3-10.9K plays a role late during the subspecies B1 HAdV life-cycle
and that the naturally occurring genetic variability documented for this ORF is likely to
impact the function of the encoded products.

Expression of ORF E3-10.9K late during infection
Species C HAdV E3-11.6K/ADP is expressed at late times pi from the MLP
(Tollefson et al., 1992). Using RT-PCR, we detected products containing ORF E3-10.9K
and the TPL at 24 h pi in cells infected with subspecies B1 HAdVs encoding different
orthologs of this ORF (Fig. 9). Additionally, we observed expression of the HA-tagged 9
kDa protein ortholog in infected cells at a late time point by immunoprecipitation and
Western blot, but we were unable to detect the protein at an early time point (Fig. 10).
The expression of the protein at the late time point was dependent on viral genome
replication, as indicated by the results of the Ara-C experiment (Fig. 10). These data
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show that, like species C HAdV E3-11.6K/ADP, subspecies B1 HAdV ORF E3-10.9K is
expressed at late times from the MLP.
The expression of E3 genes at late times post infection is not unprecedented.
Although not as abundant as the ML products, synthesis of all E3 ORFs continues at late
stages of infection (Wold et al., 1995). E3-30K encoded by species E HAdV and E3-49K
encoded by species D HAdV are of particular interest because they are located in an
analogous region of the E3 transcription unit to that of species C HAdV E3-11.6K/ADP
and subspecies B1 HAdV ORF E3-10.9K (Fig. 3). ORF E3-30K and ORF E3-49K
express products at early and late stages of infection, like other E3 ORFs, but functions
have not been determined for these products (Li and Wold, 2000; Windheim et al., 2002).
Studies have not been carried out to investigate whether ORF E3-30K and ORF E3-49K
are expressed from the MLP like species C HAdV E3-11.6K/ADP and subspecies B1
HAdV ORF E3-10.9K. If expression from the MLP is a conserved feature of ORFs
located in this region of the E3 transcription unit, then all these diverse ORFs may encode
proteins with a similar function. It would then be reasonable to hypothesize that these
proteins may be important for virion progeny egress, but may carry out this fuction by
different mechanisms of action.
There are several possible explanations for our inability to detect expression of
the HA-tagged 9 kDa protein ortholog at an early time point during infection. First, the
protein may not be expressed at early times pi.

Although we detected transcripts

containing ORF E3-10.9K at early time points during infection by RT-PCR (Fig. 9), these
transcripts may not be translated.

The presence of the TPL on transcripts greatly

enhances translation of the ORFs present on these transcripts (Logan and Shenk, 1984),
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and has been discussed previously with regards to species C HAdV E3-11.6K/ADP
enhanced protein expression at late times pi (Tollefson et al., 1992). Second, the protein
may be expressed at early times pi, but our immunoprecipitation/Western blot method
may not be sensitive enough to detect low-level expression. If this was the case, such a
low level of expression at early time points may be questionable in its biological
relevance.

Even upon overexposure of the blot and using the highest sensitivity

chemiluminescence reagents available, no product was observed, suggesting that there
truly was no expression of the HA-tagged 9 kDa protein at early times pi.
Although numerous studies have been carried out to characterize species C HAdV
gene expression, little is known about subspecies B1 HAdV gene expression. One study
comparing the E3 transcription unit of HAdV-2 to that of HAdV-3 showed a lack of
conservation of splice junctions (Signäs et al., 1986). In contrast with species C HAdV
E3-11.6K/ADP (Tollefson et al., 1992), we did not find the presence of the y-leader on
the E3 transcripts detected by our method. The y-leader is a 183 bp exon that maps to the
5’ end of the E3 transcription unit and is spliced to E3 transcripts in HAdV-2 and HAdV5 (Wold et al., 1995). This sequence is also found in 25-50% of L5 mRNA coding for
the fiber protein (Bhat and Wold, 1986; Chow et al., 1979). The y-leader is proposed to
have a role in the regulation of gene expression, but little else is known (Wold et al.,
1995). The lack of the y-leader on ORF E3-10.9K transcripts could indicate differences
in the regulation of expression for subspecies B1 HAdV compared to species C HAdV,
but further experiments are necessary to fully characterize the implications of this
observed difference.
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In addition to detecting the expression of ORF E3-10.9K from the AdV MLP, we
also detected the presence of ORF E3-20.5K on MLP transcripts. This finding was
investigated further in our lab and we detected both ORF E3-20.5K and ORF E3-20.1K
on transcripts containing the TPL at late times pi. These data led to a new hypothesis that
ORF E3-20.5K, ORF E3-20.1K, and ORF E3-10.9K may function in concert. If true, this
interaction would not be unprecedented for proteins encoded in the E3 transcription unit.
For instance, the RID complex is formed by E3-encoded proteins RIDα and RIDβ, and
the E3-6.7K protein interacts with these proteins as well (Benedict et al., 2001).
Future studies will test the new hypothesis by examining expression of the three
ORFs E3-20.1K, E3-20.5K, and E3-10.9K during infection. If the products of these three
ORFs are indeed acting together, it is likely that they could exhibit some protein-protein
interactions detectable using pull-down assays.

The generation and examination of

HAdV-3p mutant viruses lacking the ability to express proteins from one, two, or all
three of these ORFs is currently underway and will provide insight into the potential
interactions between these proteins during subspecies B1 HAdV infection.

Subcellular localization of ORF E3-10.9K-encoded proteins
The data presented here show that ORF E3-10.9K predicted proteins containing a
C-terminus and a hydrophobic domain (9 kDa and 10.9 kDa) localized primarily to the
plasma membrane (Fig. 12). The lack of a C-terminus in the 7.7 kDa ortholog resulted
in localization to an intracellular compartment, and the lack of both the hydrophobic
domain and the C-terminus in the 4.8 kDa ortholog resulted in diffuse cellular
localization (Fig. 12, 13, 14, 15). These data were consistent with the Kyte-Doolittle
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hydrophobicity predictions (Fig. 6). Additionally, our data generated from membrane
fractionation experiments using a mutant HAdV-3p virus capable of expressing an HAtagged version of the 9 kDa variant supported the hypothesis that the protein orthologs
with a hydrophobic domain localized to membranes during infection (Fig. 8).
Localization to the plasma membrane was clearly observed for the 9 kDa and 10.9
kDa protein orthologs (Fig. 12). However, we were unable to determine the exact
localization of the 7.7 kDa protein ortholog. The reason why the 7.7 kDa protein did not
localize to the plasma membrane, while the 9 kDa and 10.9 kDa proteins did remains
unclear. At this point we are unclear where the 7.7 kDa protein localized, since it did not
appear to be in the Golgi apparatus or the endoplasmic reticulum. Future studies will
investigate more specifically the localization of 7.7 kDa protein and focus on structural
analyses to understand why the 9 kDa and 10.9 kDa proteins localize to the plasma
membrane while the 7.7 kDa protein does not. Experiments carried out with species C
HAdV

E3-11.6K/ADP

mutant

viruses

examined

the

subcellular

localization,

glycosylation, and function of targeted mutant versions of E3-11.6K/ADP (Tollefson et
al., 2003).

Those experiments showed that C-terminus mutants—which would be

equivalent to the 7.7 kDa protein ortholog examined in our studies—in general displayed
normal glycosylation patterns, but different localization patterns (Tollefson et al., 2003).
The plasma membrane localization of the 9 kDa and 10.9 kDa protein orthologs
was unexpected, since we hypothesized that the proteins may have a function similar to
species C HAdV E3-11.6K/ADP.

E3-11.6K/ADP localizes primarily to the nuclear

envelope (Scaria et al., 1992).

Numerous laboratory-generated mutants of E3-

11.6K/ADP have been examined for subcellular localization and function (Tollefson et
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al., 2003). Alterations of the carboxy domain for E3-11.6K/ADP result in non-nuclear
membrane cellular localization, including localization to intracellular vesicles or all
membranes. Major alterations to remove the hydrophobic domain result in cytoplasmic
localization. Changes in the amino domain result in normal localization to the nuclear
envelope and Golgi (Tollefson et al., 2003). We made similar observations with our
naturally occurring ORF E3-10.9K-encoded protein variants: the loss of the hydrophobic
domain resulted in diffuse cellular localization, changes in the carboxy domain altered
subcellular localization, and changes in the amino domain had no affect on subcellular
localization. E3-11.6K/ADP has not been detected at the plasma membrane (Scaria et al.,
1992; Tollefson et al., 2003).
The ORF E3-10.9K-encoded protein orthologs may display a subcellular
localization when expressed from the viral genome during infection that is different from
what we observed with our ectopically expressed proteins. Any difference would likely
be due to the interaction between ORF E3-10.9K-encoded proteins and another virusencoded protein. To test this possibility, an experiment was carried out using HeLa TRExTM cells expressing EGFP-tagged ORF E3-10.9K-encoded protein orthologs. These
cells were infected with HAdV-16p, and the localization of the EGFP-tagged proteins
was examined by immunofluorescence microscopy.

Preliminary data showed no

difference in subcellular localization of the EGFP-tagged ORF E3-10.9K-encoded protein
orthologs in infected versus uninfected cells.

These experiments were discontinued

because (1) no difference was observed and (2) they were inconclusive because of our
inability to determine, and therefore replicate, the normal relative abundance of ORF E310.9K-encoded proteins during subspecies B1 HAdV infection. We also unsuccessfully
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attempted to determine the localization of the HA-tagged 9 kDa protein ortholog
expressed by the HAdV-3p-9K-HA mutant virus by immunofluorescence microscopy
using several anti-HA antibodies. All these antibodies showed high cross-reactivity with
another unknown HAdV protein (as indicated by staining of cells infected with HAdV3p-KO mutant virus), and therefore were unsuitable for detecting the localization of the
HA-tagged 9 kDa protein in infected cells. In order to further examine subcellular
localization of ORF E3-10.9K-encoded protein orthologs in infected cells, HAdV-3p
mutants could be generated that express the proteins as fusions with a different epitope
tag, such as FLAG.
Although the data presented here was obtained using an artificial system for
expression of ORF E3-10.9K-encoded protein orthologs, our findings for experiments
using the mutant HAdV-3p expressing the HA-tagged 9 kDa protein showed that this
protein localized to host cellular membranes during infection, supporting the observations
made with the EGFP-tagged proteins.

Glycosylation patterns of ORF E3-10.9K-encoded proteins
Our data showed differences in glycosylation among ORF E3-10.9K-encoded
protein orthologs. Whereas the 4.8 kDa variant showed no evidence of glycosylation, the
7.7 kDa, 9 kDa, and 10.9 kDa variants did (Fig. 11A). The 7.7 kDa and 10.9 kDa showed
evidence of both O- and N-linked glycans, while the 9 kDa showed evidence of only Nlinked glycans (Fig. 11B). The major difference between the 9 kDa protein ortholog and
the 10.9 kDa and 7.7 kDa protein orthologs is a deletion in the N-terminus (Fig. 7). This
observation suggested that O-linked glycans were present on the N-terminus of the
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protein, or that the O-linked glycosylation required the presence of this N-terminus
domain that was missing in the 9 kDa protein ortholog.
Also intriguing was our observation that treatment with glycosidases to remove
both N- and O-linked glycans did not result in the complete return of the protein
electrophoretic mobility to that of the expected native protein (Fig. 11). This finding
could be explained by the lack of complete digestion of the protein, but a control
digestion using glycosylated fetuin protein confirmed complete digestion (data not
shown). Another, more probable explanation, is that there were other O-linked glycans
present on the proteins that were not removed by treatment with O-glycosidase and
neuraminidase. Treatment with these two glycosidases removes most, but not all, Olinked glycans.

More complicated experiments could be performed using other

glycosidases to test this possibility.

Another possibility is that a post-translational

modification other than glycosylation is present on these proteins.
The implications of the differences in glycosylation patterns for ORF E3-10.9Kencoded protein orthologs are currently unknown. Although the role of glycosylation for
protein function varies widely, analysis of E3-11.6K/ADP mutants indicate that
glycosylation serves to stabilize the protein (Tollefson et al., 2003). Other roles for
glycosylation include protein-protein interactions, proper folding of proteins, and
maintenance of protein solubility and conformation (Varki and Lowe, 2009).

Membrane destabilizing activity of ORF E3-10.9K-encoded protein orthologs
Our data showed that, although ORF E3-10.9K-encoded protein orthologs with a
hydrophobic domain permeabilized membranes in a bacterial expression system, they did
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not appear to permeabilize membranes in a mammalian expression system (Fig. 16, 17).
These data suggest that our hypothesis that these proteins may be acting through a
membrane destabilizing mechanism is not correct. However, several questions are raised
by these experiments.
First, why did the proteins permeabilize bacteria but not mammalian cells? One
possible explanation could be our method for assessing permeabilization.

For the

bacteria expression system, we tested whether the cells became permeable to propidium
iodide by flow cytometry. For the mammalian expression system, we tested whether the
cells became permeable to trypan blue by light microscopy. Although both propidium
iodide and trypan blue are both membrane impermeant dyes, propidium iodide is slightly
smaller (668.4 Da) than trypan blue (872.8 Da). Propidium iodide is a DNA/RNA
intercalating fluorescent dye that increases in fluorescence 20-30 times upon binding of
nucleic acid. We detected this fluorescence using a flow cytometer. Trypan blue is a
diazo dye that upon entry into a cell with a non-intact plasma membrane will bind
proteins. Stained cells are readily distinguishable from unstained cells by their blue
appearance under a light microscope. Although trypan blue and propidium iodide are
similar in size, the sensitivity of the propidium iodide assay is likely higher than the
trypan blue assay. It is possible that the mammalian cells in our experiments were
permeable to trypan blue, but not enough of the dye was able to enter the cells to provide
a difference distinguishable by light microscopy. We would expect a higher sensitivity in
our flow cytometry experiment detecting propidium iodide stained cells.

However,

trypan blue has been successfully used to detect the disruption of mammalian cells by
membrane-active peptides (Zhang et al., 2009), suggesting that our data reflected a lack
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of permeabilizing ability of ORF E3-10.9K-encoded protein orthologs in mammalian
cells.
A method potentially more sensitive than trypan blue staining was tested as an
alternative: Oregon-green diacetate (OGDA)-release assay. HeLa T-RExTM cells were
loaded with OGDA and then expression of ORF E3-10.9K-encoded protein orthologs
was induced with tetracycline. Unfortunately, we were unable to obtain results from this
experiment because of the quick release of OGDA after loading, which is a common
occurrence with cells of epithelial origin (personal communication with Molecular Probes
technical support representative).

We also carried out a propidium iodide uptake

experiment with HeLa T-RExTM cells, but overlap of propidium iodide and EGFP
fluorescence signals made the data hard to interpret. The preliminary data we obtained
from these experiments showed no permeabilization of the mammalian cells to propidium
iodide upon expression of ORF E3-10.9K-encoded protein orthologs.

These results

should be interpreted with caution because of the unreliable nature of the data and
therefore were not included in this dissertation.
Another explanation for the differences in our findings using bacterial and
mammalian expression systems is the structural differences between bacterial and
mammalian membranes. Bacterial expression systems are used extensively for
structure/function studies of viroporins and other membrane-active proteins because of
their simplicity and the ease with which experiments can be carried out (Gonzales and
Carrasco, 2005).

However, our data suggested that results obtained with bacterial

expression systems should be interpreted with caution when the protein being examined
is normally expressed in a mammalian cell, as most viroporins are.
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Both the mammalian and bacterial expression systems were artificial in that we
were examining proteins likely overexpressed compared to their native counterparts
expressed during the course of infection. However, overexpression of GST alone or
GST-4.8 kDa in bacteria did not result in permeabilization of the cells to propidium
iodide (Fig. 16), indicating that the permeabilization observed with 7.7 kDa, 9 kDa, and
10.9 kDa was due to some intrinsic membrane activity of these proteins and not to an
artifact of overexpression. Additionally, the lack of permeabilization of mammalian cells
overexpressing EGFP-tagged ORF E3-10.9K-encoded protein orthologs (Fig. 17)
suggested that at lower levels of expression expected in the context of infection, no
membrane destabilization would occur.
Alternative approaches to measure membrane permeability include liposomebased assays, hygromycin B inhibition of protein translation, and Merocyanine 540
(MC540) assays.

For liposome-based assays, purified proteins are mixed with

fluorescent dye-loaded liposomes and the release of dye is measured with a fluorimeter
(Agirre et al., 2002; Top et al., 2005). These experiments require the purification or
synthetic production of the proteins of interest, which can be difficult for highly
hydrophobic, and therefore poorly soluble, proteins such as viroporins and ORF E310.9K-encoded protein orthologs. Studies of membrane permeabilizing activity of
viroporins often use Hygromycin B assays (Han and Harty, 2004; Lama and Carrasco,
1996; Liao et al., 2006; Madan et al., 2005; Suzuki et al., 2010). Hygromycin B is a
protein translation inhibitor that is usually excluded by cellular membranes.

Upon

expression of a membrane-permeabilizing protein, hygromycin B is able to enter cells
(bacterial or mammalian) and inhibit de novo protein translation. These studies are
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complicated by the fact that the translation of the proteins inducing the cells to become
permeable to hygromycin B is also down-regulated as a consequence of the experiment
(Lama and Carrasco, 1992). Also, hygromycin B is only excluded from cells at low
concentrations, making the experiment difficult to control.

MC540 is a lipophilic

fluorescent dye that binds to the outer leaflet of plasma membranes and is sensitive to
differences in lipid packing (Lelkes et al., 1980; Stillwell et al., 1993; Williamson et al.,
1983). When MC540-labelled cells express a membrane-active protein, the fluorescence
intensity of the dye decreases and can be measured by flow cytometry (Suzuki et al.,
2010).

However, the change in fluorescence intensity of the dye only indicates

alterations to membrane structures, and does not allow conclusions about the mechanism
(Wilson-Ashworth et al., 2006).
The ORF E3-10.9K-encoded protein orthologs with a hydrophobic domain may
alter membrane structure in a way that does not result in permeabilization. The alteration
of membrane structure could be causing some other effect, as yet to be determined.

Role of ORF E3-10.9K in subspecies B1 HAdV growth and progeny virion egress
Our data does not support the hypothesis that ORF E3-10.9K-encoded protein
orthologs are involved in the efficient release of progeny virions from infected cells at the
end of infection. We observed no differences between control and ORF E3-10.9K
mutant viruses in terms of virus growth, egress, dissemination, or plaque size (Fig. 19,
20, 21, 22). Moreover, no differences were observed in the kinetics of host cell death
(Fig. 23). Species C HAdV mutants lacking E3-11.6K/ADP show a marked decrease in
the egress of viral progeny from infected cells and slower kinetics of host cell death
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(Tollefson et al., 1996b). The data reported herein are in direct opposition to our stated
hypothesis, and lead to the conclusion that ORF E3-10.9K-encoded protein orthologs are
not the subspecies B1 HAdV equivalent of species C HAdV E3-11.6K/ADP.
The ORF E3-10.9K-encoded protein orthologs may play a role in the release of
progeny virions in a way not subject to study by examination of growth phenotypes.
Human lung epithelial cells naturally exist in a stratified, differentiated state with distinct
apical and basolateral surfaces. The ORF E3-10.9K-encoded protein orthologs may play
a role in the release of progeny virions during infection only when cells are polarized. To
investigate the role of ORF E3-10.9K on the apical and basolateral egress of progeny
virions, human epithelial cells grown in air-liquid interface cultures could be infected
with our HAdV-3p mutant viruses and examined for any observable differences in their
preferential release of progeny virions. Our choice of A549 cells for the experiments
described in this dissertation was based on differences observed using this system for
species C HAdV E3-11.6K/ADP mutant viruses (Scaria et al., 1992; Tollefson et al.,
1992; Tollefson et al., 1996a; Tollefson et al., 1996b; Tollefson et al., 2003). Even if
ORF E3-10.9K-encoded protein orthologs play a role in the efficient release of progeny
virions in polarized epithelial cells, we can still conclude that ORF E3-10.9K-encoded
protein orthologs are not the subspecies B1 HAdV counterpart of species C HAdV E311.6K/ADP since the use of the same experimental system did not yield similar results.
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Implications of ORF E3-10.9K polymorphism for subspecies B1 HAdV evolution and
fitness
The observed differences in subcellular localization and glycosylation of the
products encoded by naturally occurring variants of ORF E3-10.9K suggest functional
implications for these mutations. We predict that the 4.8 kDa protein ortholog, and other
protein orthologs without a hydrophobic domain, will display a defective function.
Additionally, mutations in the carboxy domain will likely impact the protein function as
well, since the 7.7 kDa protein shows different subcellular localization.
A trend toward truncation or loss of coding capability for ORF E3-10.9K among
circulating strains of HAdV-3 and HAdV-7 was detected in recent molecular
epidemiology studies conducted by our lab (L. Dickson, A. Dowling, K. Frietze, A.
Kajon, unpublished data). Upon sequencing ORFs E3-10.9K, E3-20.1K, and E3-20.5K
for the genomes of geographically and temporally diverse subspecies B1 HAdV field
isolates, we observed that currently circulating disease-associated HAdV-7 and HAdV-3
genomic variants encoded versions of ORF E3-10.9K that were either truncation variants
without a hydrophobic domain or null variants with mutations of the start codon.
However, HAdV-21 and HAdV-16 isolates did not show this same trend. All HAdV-21
and HAdV-16 isolates sequenced were found to retain the ability to encode the 10.9 kDa
ortholog. The reason for this difference in the trend toward truncation of ORF E3-10.9K
among subspecies B1 HAdVs is unclear. HAdV-7 and HAdV-3 are far more commonly
isolated than HAdV-21 and HAdV-16. This difference in isolation frequency could be
due to differences in fitness and transmissibility but also to differences in pathogenicity.
Data from molecular epidemiological studies are being examined further and will
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hopefully yield important information regarding the evolution of ORF E3-10.9K
specifically, as well as the evolution of the subspecies B1 HAdV E3 transcription unit.
The apparent trend toward truncation of ORF E3-10.9K for HAdV-7 and HAdV-3
genomic variants can be explained in several ways. First, there may be no selective
pressure to maintain ORF E3-10.9K within these genomes, which could lead to
truncation or loss since any mutations that occur would have no consequence to the
fitness of the virus. In this case, the theoretical original function of ORF E3-10.9K may
now be served by another virus-encoded product or the ORF might never have had a
function for the virus. Second, there may be a selective pressure against having ORF E310.9K. In this case, there would be selection against variants that encode ORF E3-10.9K,
leading to a change in the prevalence of the circulating HAdV-7 and HAdV-3 that do not
have ORF E3-10.9K. In this case, having ORF E3-10.9K would be detrimental to the
virus, so those viruses without ORF E3-10.9K would have a selective advantage. Third,
the apparent increase in circulating strains of HAdV-7 and HAdV-3 that do not encode
ORF E3-10.9K could be due to sampling bias. In this case, viruses encoding ORF E310.9K may not cause severe disease, and so would be poorly represented in a sample of
field isolates from symptomatic individuals. This explanation is attractive when taking
into account that HAdV-7 and HAdV-3 genomic variants that encode ORF E3-10.9K
versions with a hydrophobic domain are infrequently isolated. In order to distinguish
between these three possibilities, sampling of asymptomatic individuals would be
necessary.
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Future directions
If the products of ORF E3-10.9K are not the subspecies B1 HAdV equivalents of
species C HAdV E3-11.6K/ADP, several questions must be answered: (1) Is there
another protein(s) encoded by subspecies B1 HAdVs serving the function of facilitating
viral progeny exit? (2) Do subspecies B1 HAdVs not require an E3-11.6K/ADP-like
biological activity to be successful? (3) What is the role of ORF E3-10.9K-encoded
proteins if not to facilitate efficient release of virus progeny?
Our revised hypothesis based on the data reported here is that ORF E3-10.9Kencoded protein orthologs serve a function at late stages of infection, possibly by
interacting with the products of ORF E3-20.1K and/or ORF E3-20.5K.

What that

function may be is an open question. At late stages of AdV infection, the primary protein
products expressed are structural proteins, which are assembled along with new viral
genomes into progeny virions. For species C HAdV, E3-11.6K/ADP is also expressed at
late stages of infection and plays a role in the release of progeny virions. Since ORF E310.9K-encoded products are expressed late during infection, but are not structural
proteins, it is reasonable to hypothesize that this ORF plays a role in the efficient release
of progeny virions. However, our data suggest that ORF E3-10.9K-encoded protein
products are not the subspecies B1 HAdV equivalent of species C HAdV E3-11.6K/ADP.
What other role might ORF E3-10.9K-encoded protein products be playing late
during infection? The E3 transcription unit primarily encodes products that modulate the
host response to infection (Burgert and Blusch, 2000). Although the viral products
involved in altering the host immune response are primarily important for early stages of
infection, ORF E3-10.9K-encoded protein products may be modulators of the host
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immune response at late stages. An investigation of our HAdV-3p ORF E3-10.9K
mutant viruses in an animal model would be ideal for determining the potential roles of
this ORF in viral pathogenesis. However, animal models currently available are only
suitable for examination of early stages of infection, since they are not permissive for
viral replication and late gene expression (Ginsberg et al., 1989; Sparer et al., 1996). At
this point, future experiments are limited to cell culture-based systems. An analysis of
the potential role of ORF E3-10.9K in the modulation of the immune response could be
carried out by examining the expression of cytokines, chemokines, or other immunerelated genes using a cell culture-based experimental system.
There is a suggestion that adenovirus progeny are released via an autophagyrelated mechanism rather than the assumed lysis mechanism (Ito et al., 2006; Jiang et al.,
2007; Jiang et al., 2008). Studies investigating the mechanism of cell death of AdVinfected cells were carried out using conditionally replicating HAdV-5 with a deletion of
the Rb-binding domain of E1A (Fueyo et al., 2000). Although autophagy is implicated as
a mechanism of cell death induced by these viruses, the presence or absence of the E3
transcription unit has no effect on the type of cell death resulting from infection (Abou El
Hassan et al., 2004), suggesting that the E3-11.6K/ADP is not involved in the proposed
autophagic mechanism of cell death. Additionally, an investigation of autophagic modes
of cell death in cells infected with non-mutant AdV has not been carried out, but would
be essential to establishing the role of autophagy in AdV progeny release and host cell
death.

If the role of autophagy in natural AdV infection is confirmed, further

investigations of subspecies B1 HAdV ORF E3-10.9K function could include
examinations of the role of this ORF in autophagic mechanisms of host cell death.
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Conclusion
Our data support the conclusion that ORF E3-10.9K is not the subspecies B1
HAdV equivalent of the species species C HAdV E3-11.6K/ADP. This conclusion is
based on the observation that, unlike species C HAdV E3-11.6K/ADP, (1) the ORF E310.9K-encoded protein orthologs do not localize to the nuclear envelope (Fig. 12-15), and
(2) HAdV-3p ORF E3-10.9K mutant viruses unable to express a polypeptide show no
difference in virus-induced CPE (Fig. 19), dissemination in cell monolayers (Fig. 20),
plaque size (Fig. 21), progeny virus egress (Fig. 22), or host cell killing (Fig. 23). A
summary schematic of this conclusion is shown in Figure 24.
Although our data do not support our hypothesis of a role for ORF E3-10.9Kencoded protein products in the efficient release of progeny virions through
destabilization or permeabilization of host membranes, we did obtain data to support the
conclusion that ORF E3-10.9K-encoded protein orthologs are likely to play a role for
subspecies B1 HAdVs during late stages of infection. Additionally, our data support the
hypothesis that the naturally observed variation within ORF E3-10.9K is likely to have a
functional significance for subspecies B1 HAdV infections. Future experiments should
focus on further ascertaining the function of ORF E3-10.9K-encoded protein orthologs,
investigating their potential interactions with other viral proteins (including ORF E320.1K- and ORF E3-20.5K-encoded protein products), and elucidating the impact of the
striking variation present among subspecies B1 HAdVs in ORF E3-10.9K for virus
fitness and evolution.
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Figure 24. ORF E3-10.9K is not the subspecies B1 HAdV equivalent of the species
C HAdV E3-11.6K/adenovirus death protein. The data presented herein support a
model for subspecies B1 HAdV egress that is different from that of species C HAdV. In
species C HAdV, E3-11.6K/ADP is expressed at late times post infection, localizes to the
nuclear envelope, and facilitates efficient progeny virion egress. Species C HAdVs
unable to express E3-11.6K/ADP retain progeny virions in the nucleus, resulting in
inefficient egress at the end of infection. In subspecies B1 HAdV, ORF E3-10.9K
proteins are expressed at late times post infection, but do not localize to the nuclear
envelope. Instead the ORF E3-10.9K protein orthologs localize to either the plasma
membrane (10.9 kDa and 9 kDa), an intracellular compartment (7.7 kDa), or throughout
the cell (4.8 kDa). Subspecies B1 HAdV progeny virions egress efficiently from the host
cell regardless of their ability to express an ORF E3-10.9K-encoded protein ortholog.
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Appendix A: Acronyms
ADP
AdPol
AdV
Ara-C
CPE
DBP
E3
EGFP
EMEM
GST
HAdV
HAdV-# (e.g. HAdV-3)
ICTV
ITR
ML
MLP
MOI
OGDA
ORF
pi
PFU
pTP
RID
SP
TNFα
TPL
VA RNA
WGA-647

Adenovirus death protein
Adenovirus DNA polymerase
Adenovirus
Cytosine β-D-arabinofuranoside hydrochloride
Cytopathic effect
DNA binding protein
Early region 3
Enhanced green fluorescent protein
Eagle Minimum Essential Medium
Glutathione-S-transferase
Human adenovirus
Human adenovirus serotype #
International Committee on the Taxonomy of Viruses
Inverted terminal repeats
Major late transcription unit
Major late promoter
Multiplicity of infection
Oregon green diacetate
Open reading frame
Post infection
Plaque forming units
Pre-terminal protein
Receptor internalization and degradation
Sequence profile
Tumor necrosis factor alpha
Tripartite leader
Virus associated RNA
Wheat germ agglutinin-647
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